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“Et es wie et es. Et kütt wie et kütt. Et hät noch immer joot jejange. Wat fott es, es 
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1 Introduction 
1.1 Pluripotent Stem Cells 
Since the 1980´s, research of pluripotent stem cells (PSCs) is in focus of life 
sciences. PSCs have two characteristic features that distinguish them from other 
cells. First, PSCs are pluripotent, meaning that each single cell can generate all cell 
lineages of the developing and adult organism, and second they have the ability to 
self-renewal. Because of that, PSCs hold great promises as a model for development 
and as a source for cells in regenerative medicine.  
 
1.1.1 Embryonic Stem Cells 
Murine embryonic stem cells (mESCs) were derived more than 30 years ago for the 
first time (Evans & Kaufman, 1981). From the beginning researchers were interested 
in those cells derived from the preimplantation embryo blastocyst at stage E3.5, as 
they could differentiate them into cells of all three germ layers; but until 1998 they did 
not succeed in deriving the human counterpart.  
In 1998, Thomson and his colleagues could isolate human embryonic stem cells 
(hESCs) for the first time from the inner cell mass (ICM) of the blastocyst of a pre-
implantation embryo (Thomson et al., 1998). Because an embryo has to be 
destroyed for the derivation of hESC lines, ethical and depending on the country also 
legal issues limit the ability to work with those cells.  
 
1.1.2 Induced Pluripotent Stem Cells 
In 2006, Takahashi and Yamanaka could reprogram somatic cells into so called 
induced pluripotent stem cells (iPSCs) by introducing the four key pluripotency 
factors Oct-3/4, Sox2, Klf4 and c-Myc genetically (Takahashi & Yamanaka, 2006). 
First, they reprogrammed murine fibroblasts into murine iPSCs (miPSCs), one year 
later they succeeded to generate human iPSCs (hiPSCs) by transfecting human 
dermal fibroblasts with the same four factors (Takahashi et al., 2007).  
iPSCs resemble ESCs in their characteristics, they are also pluripotent, meaning they 
have the potential to differentiate into cells of the three germ layers, and can be 
maintained in culture indefinitely. There are two major advantages of reprogrammed 
cells; first they do not raise ethical or legal concerns because no embryo has to be 
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sacrificed. Second in case of human clinical applications patient-specific cells can be 
differentiated from hiPSCs generated by reprogramming patient cells. 
So far, the generation of iPSCs has been improved continuously. Different protocols 
were established, where factors could be omitted or be replaced by small molecules; 
different cell types were reprogrammed. The efficiencies increased from initially 
0.02% to up to 25% for mouse but only from 0.02% to 0.75% for human cells (Eminli 
et al., 2009; Sugii et al., 2010; Takahashi & Yamanaka, 2006; Takahashi et al., 
2007). In murine reprogramming, principally every diploid cell type can be used as 
initial cell (Stadtfeld & Hochedlinger, 2010; Takahashi & Yamanaka, 2006). Mostly, 
mouse embryonic fibroblasts (MEFs) or adult tail tip fibroblasts (TTFs) are used. The 
requirements for human somatic cells as a starting point are more distinct; it is 
favorable that the cells are easy to obtain without harming the donor. Until now, 
different human cell types, for example fibroblasts, keratinocytes and cord blood 
cells, could be reprogrammed (Aasen et al., 2008; Giorgetti et al., 2009; Takahashi et 
al., 2007). 
 
1.1.3 Differences between human and murine PSCs 
Because of the better accessibility, a lot of research has been performed on murine 
pluripotent stem cells. But notably, human pluripotent stem cells differ from their 
murine counterparts in essential characteristics.  
The first difference already becomes evident observing the morphology. While 
mPSCs grow in dome shaped three-dimensional colonies, hPSCs grow in flattened 
two-dimensional colonies. 
Murine and human PSCs also differ in their cultivation behavior. In cell culture, 
murine PSCs can be grown clonogenic, meaning that the cells can be singularized, 
and each single cell gives rise to a new colony. Human PSCs need to be splitted in 
small cell clumps; clonogenicity can only be achieved when the cells are treated with 
an inhibitor of the Rho kinase, a so-called ROCK inhibitor (ROCKi) (Watanabe et al., 
2007). This property makes manipulation of human PSCs hard to achieve, as single 
manipulated cells can not be grown to a monoclonal population easily (Buecker et al., 
2010).  
A molecular difference of murine and human PSCs is the occurrence of characteristic 
cell surface antigens. While SSEA-1 (stage-specific embryonic antigen 1) is a marker 
for pluripotency in mouse cells, in human cells it is a differentiation marker 
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(Brambrink et al., 2008; Henderson et al., 2002). Distinct markers for pluripotency in 
human PSCs are the stage-specific embryonic antigens 3/4 (SSEA-3/4) (Sato et al., 
2003).   
The most striking and probably most important difference between murine and 
human PSCs lies in the signaling pathways that need to be activated to maintain their 
pluripotency. The following chapter will give an insight into the main signaling 
pathways. 
 
1.2 Signaling in PSCs for pluripotency maintenance 
Pluripotent stem cells are cell culture artifacts that do not exist over a longer time in 
vivo. Therefore distinct signaling pathways need to be activated to maintain them in 
culture. Human and murine PSCs differ in these pathways.  
 
1.2.1 Pluripotency maintenance in human PSCs 
Maintenance of human PSCs requires the addition of different extrinsic factors to the 
cell culture media. In the absence of these factors, hPSCs lose their pluripotency and 
differentiate spontaneously.  
Standard culture of hPSCs depends on a layer of so-called feeder cells, mouse 
embryonic fibroblasts (MEFs) that are irradiated to prevent an overgrowing of the 
hPSCs culture (Thomson, 1998). Addition of the extrinsic factors stimulates the 
fibroblasts to secrete other factors important for maintaining pluripotency. To remove 
murine cells from the human PSC culture, medium can be conditioned by feeder 
cells. After filtration, the medium contains no cells. In recent feeder-free cultivation 
protocols the conditioning of the medium by MEFs is not required. All needed factors, 
such as bFGF and Activin A, are supplied with the defined cell culture medium. A 
standard medium commercially available is mTeSR™-1; more recently, a medium 
with only eight components was published and due to the number named E8 (Chen 
et al., 2011; Ludwig et al., 2006). 
 
bFGF signaling 
Basic fibroblast growth factor (bFGF or FGF2) signaling is activated in hPSC culture 
by adding the recombinant protein directly to the culture. The way in which bFGF 
promotes hPSC propagation is still poorly understood. It is known that bFGF 
Introduction 
 
! 4 
activates the mitogen-activated protein kinase (MAPK) and thus MAPK/ERK 
signaling (Eiselleova et al., 2009). In general, bFGF promotes proliferation, which is 
why it is supplemented to a variety of cell culture media for different cell types 
(Jirmanova et al., 1999; Kotev-Emeth et al., 2002; Luo & Miller, 1997). In 2000, it was 
reported that bFGF is required for prolonged undifferentiated proliferation of hESCs 
(Amit et al., 2000). More recently, it was reported that inhibition of FGF/ERK signaling 
leads to a rapid downregulation of NANOG. Additionally, OCT4 binds to the FGF2 
reporter and thus regulates its activation in an autocrine manner (Greber et al., 
2010). This indicates a connection of FGF signaling with two core pluripotency-
associated transcription factors.  
Furthermore it has been shown that, while low levels promote stem cell maintenance, 
high activity of ERK signaling promotes differentiation. To control the activity of ERK 
signaling, high concentrations of FGF2 do not only activate MAPK/ERK signaling but 
also PI3K/AKT signaling. PI3K/AKT signaling itself suppresses MAPK/ERK signaling 
and thereby prevents too high levels of ERK (Singh et al., 2012). 
 
Activin A signaling 
Together with Nodal, Inhibins and BMPs (bone morphogenic protein), Activin A forms 
the Tgf! superfamily. In mPSCs, BMP is essential to maintain pluripotency (Ying et 
al., 2003). When supplemented in human PSC cultures, BMP leads to differentiation 
into trophectoderm (Xu et al., 2002).   
However, another member of the Tgf! superfamily, Activin A, is an important 
extrinsic factor for hPSC maintenance culture. Activin A mediates, together with 
Nodal, pluripotency via Smad-2/3 signaling. In 2008, Xu et al. reported that the 
pluripotency-related transcription factor Nanog is a direct target of Activin A/Smad-
2/3 signaling, highlighting the importance of this pathway (Xu et al., 2008). 
Furthermore, Activin A is able to induce the expression of other pluripotency 
regulators such as Oct4, Nodal, Wnt3 and also bFGF (Xiao, Yuan, & Sharkis, 2006). 
Other members of the Tgf! family, such as TGF! itself and Nodal, can substitute for 
Activin A (Xu et al., 2008).  
In co-culture with feeder cells, bFGF stimulates the fibroblasts to secrete Activin A 
(Beattie et al., 2005; Eiselleova et al., 2008). In feeder-free cultivation systems, 
Activin A has to be supplemented. Vallier showed in 2005 that the combination of 
bFGF and Activin A supplementation enabled hPSC culture without feeder cells, 
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conditioned medium or serum replacement by controlling Nanog expression (Vallier 
et al., 2009; Vallier, Alexander, & Pedersen, 2005).  
 
Other pathways 
The feeder-dependent first-generation hPSC maintenance protocols all include cell 
culture media containing either fetal calf serum (FCS) or knockout serum 
replacement (KOSR). These components are not chemically defined and contain 
factors such as IGF and insulin. The containing factors stimulate a variety of 
signaling pathways that may also be part of the self-renewal signaling network. For 
instance, IGF and insulin activate the canonical phosphatidylinositol-3 kinase (PI3K) 
signaling pathway, which also plays a critical role in murine PSC maintenance 
(Bendall et al., 2007; Watanabe et al., 2006).  
Controversial reports about the role of Wnt signaling in hPSCs have been published. 
Fibroblasts of the feeder layer secrete several activators of Wnt signaling. In 2004, 
Sato et al. showed that Wnt signaling prevents differentiation in hESCs (Sato et al., 
2004). Conflicting with that, it has been reported that active Wnt signaling promotes 
differentiation of hPSCs (Bone et al.,  2011; Davidson et al., 2012).  
 
1.2.2 Pluripotency maintenance in murine PSCs 
As described for hPSCs, mPSCs initially were cultivated on a feeder layer of MEF 
cells. In 1988, Smith as well as Williams identified factors that made the feeder cells 
dispensable. One of these factors, the most prominent factor in mPSC maintenance, 
is the Leukemia Inhibitory Factor (LIF) (Smith et al., 1988; Williams et al., 1988). 
 
LIF signaling 
The Leukemia Inhibitor Factor (LIF) is a member of the IL-6 family. It is an essential 
extrinsic factor in the cultivation of murine PSCs. LIF maintains pluripotency via 
binding to the LIF receptor (LIFR), which then forms a heterodimer with the signal-
transducing transmembrane glycoprotein 130 (gp130). This leads to a Janus kinase 
(Jak) mediated phosphorylation of the signal transducer and activator 3 (Stat3). 
Phosphorylated and thereby activated Stat3 (p-Stat3) molecules form homodimers 
and translocate into the nucleus where they bind to the DNA and activate target gene 
transcription (Zhong, Wen, & Darnell, 1994). Still, it is not fully understood how 
LIF/Stat3 signaling maintains mPSC pluripotency. In 2013, Tai and Ying published 
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that gastrulation brain homeobox 2 (Gbx2) is a target of LIF/Stat3 signaling. 
Overexpression of Gbx2 maintains mPSC pluripotency in the absence of LIF/Stat3 
signaling and improves reprogramming efficiency. Furthermore, when 
overexpressed, Gbx2 is sufficient to reprogram murine epiblast stem cells (derived 
from the epiblast; mEpiSCs) into ground state mESCs (Tai & Ying, 2013).   
A connection between the extrinsic LIF signaling and the intrinsic transcription factor 
Nanog was described in 2009 by Niwa et al. LIF activates T-box 3 (Tbx3) via PI3-
kinase/Akt-signaling, which itself induces Nanog expression. Furthermore they could 
show that also the intrinsic transcription factor Klf4 is activated through LIF signaling 
via Jak/Stat-signaling (Niwa et al., 2009). Correspondent to these findings, for the 
maintenance of pluripotency in mPSCs in the absence of LIF, either overexpression 
of Stat3 or Nanog is sufficient (Matsuda et al., 1999; Mitsui et al., 2003). Stat3-
knockout-mPSCs can be kept pluripotent when the so-called 2i medium is applied. 
Double inhibition of GSK3 and MEK with small molecule inhibitors can compensate 
for lack of LIF signaling (Ying et al., 2008).  
 
BMP signaling 
Under serum free conditions, LIF alone fails to maintain pluripotency. mPSCs tend to 
differentiate into the neuronal lineage upon serum withdrawal (Ying et al., 2003). 
Addition of Bone Morphogenic Protein (BMP) could, together with LIF, prevent 
differentiation. BMP binds two forms of cell surface receptors, namely BMP receptor 
type I (BMPRI) and type II (BMPRII). The binding of BMP leads to heterodimerization 
of the both receptors. These heterodimers phosphorylate different Smad proteins (1, 
5 and 8). The activated Smad proteins form itself heterodimers with co-Smad 4 that 
translocate into the nucleus where they bind to promoter regions of BMP target 
genes and thereby activate their expression (Chen, Zhao, & Mundy, 2004; Miyazono, 
1999).   
Another proposed role for BMP is the inhibition of p38, a tumor suppressor, which 
inhibits expression of pluripotency-associated genes (Qi et al., 2004).  
 
Wnt signaling 
In Wnt signaling, Wnt binds to its receptor Frizzled that then activates Dishevelled. 
Active Dishevelled inhibits GSK3, Axin and APC to form a complex. The complex 
phosphorylates !-catenin, which then is degraded. In the presence of a Wnt ligand, 
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!-catenin is not phosphorylated and therefore can, together with TCF and Lef, induce 
gene transcription (Barker, Morin, & Clevers, 2000).  
It has been reported that in mPSCs TCF represses genes that antagonize stem cell 
maintenance and therefore would lead to differentiation when expressed (Sokol, 
2011).  
 
1.2.3 Naïve versus primed pluripotency 
While mPSCs need to be cultured in the presence of leukemia inhibitory factor (LIF), 
hPSCs do not respond to LIF with the activation of the LIF-Stat3 signaling pathway. 
In 2004, Daheron et al. reported that LIF/Stat3 signaling cannot maintain hESC 
pluripotency (Daheron et al., 2004). In contrast, they need the addition of basic 
fibroblast growth factor (bFGF) and the presence of Activin A and Nodal to remain 
pluripotent (for summary see Figure 1.1). 
 
 
Figure 1.1: Summary of the different pathways that need to be activated in mPSCs and 
hPSCs/mEpiSCs  
(Zhang, Krawetz, & Rancourt, 2013) 
 
Although both cell populations are derived from the inner cell mass of the blastocyst 
stage, they seem to represent different developmental stages (Najm et al., 2011).  
Cells that are isolated from the epiblast stage of murine postimplantation embryos at 
E 5.5 (murine epiblast stem cells, mEpiSCs) resemble hPSCs. In 2007 it was shown 
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that mEpiSCs show the same morphology as hPSCs as they are growing in two-
dimensional colonies. They can not be splitted as single cells, which is a 
characteristic of mPSCs (Brons et al., 2007; Tesar et al., 2007). Furthermore, 
mEpiSCs can not contribute to chimeras, which is an important test for pluripotency 
in mPSCs, but they efficiently form teratomas and embryoid bodies, showing that 
they have the ability to differentiate into all three germ layers (Guo et al., 2009; Tesar 
et al., 2007). 
Another difference between mEpiSCs/hPSCs and mPSCs is the activation-state of 
the X chromosomes in the female cells. In mEpiSCs and hPSCs, only one X 
chromosome is active, the other is inactivated by XIST. Female mPSCs contain two 
active X chromosomes (Okamoto et al., 2004).  
As the chimera-assay cannot be performed with human cells for ethical reasons, 
other primate ESCs that resemble hPSCs were tested for their potential to contribute 
to chimeras. Rhesus monkey ESCs can not efficiently home into the inner cell mass 
of preimplantation blastocysts and thus not generate chimeric monkeys, suggesting 
that primate PSCs correspond to a rodent primed pluripotent state (Tachibana et al., 
2012).  
Overall, mEpiSCs seem to represent the same developmental stage as hPSCs, 
which is obviously later than the mPSCs. Therefore, the state represented by the 
mPSCs is referred to be the naïve pluripotency, whereas mEpiSCs and hPSCs are in 
a primed state (Nichols & Smith, 2009). The characteristics of the naïve and the 
primed pluripotent state are summarized in Table 1.1. 
 
Table 1.1: Characteristics of naïve and primed pluripotency (adapted from Gafni et al., 
2013) 
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A lot of effort has been made to find the naïve counterpart of hPSCs. It would be 
favorable to have human naïve stem cells, because it would allow insights into 
human development. Furthermore, naïve hPSCs could be plated as single cells; the 
clonogenicity would permit the translation of gene targeting technologies thus far 
restricted to murine cells and therefore accelerate dissection of the human genome.   
In 2010, attempts to isolate naïve hESCs from human embryos failed. Lengner and 
his colleagues were able to derive female hESCs with two activated X chromosomes 
in conventional hESC medium with FGF when the embryos are kept under low-
oxygen conditions (5% O2). Female hESCs that are obtained from embryos under 
atmospheric oxygen conditions show an upregulation of XIST and an inactivated X 
chromosome (Lengner et al., 2010). However, it is not reported whether other 
features associated with naïve ESCs are displayed by the cells with two active X 
chromosomes. Two other studies reported the attempt to obtain naïve hESCs by 
applying 2i conditions (MEK and GSK3 inhibition) to human embryos. In both cases 
naïve hESCs could not be isolated (Kuijk et al., 2012; Roode et al., 2012). 
The first successful attempt to directly reprogram human fibroblasts to cells that 
resemble mESCs was reported in 2009. Lentiviral introduction of the pluripotency 
factors OCT4, SOX2, NANOG and LIN28 together with the cultivation in 2i conditions 
and additional inhibition of ALK4/5/7 with the small molecule inhibitor A-83-01 results 
in cells that can be cultured in presence of LIF/2i for more than 20 passages. 
However, transgene-independency can not be confirmed, as the transgenes are not 
silenced properly (Li et al., 2009). 
In 2010, Hanna et al. obtained human embryonic stem cells with biological and 
epigenetic characteristics similar to those of mESCs by switching the media 
conditions to the so called 2i conditions and ectopically expressing Oct4 and Klf4 or 
Klf4 and Klf2. The expression system is dox-inducible and after dox withdrawal the 
cells change back to the primed state (Hanna et al., 2010).  
Only few attempts have published the aim to revert primed hPSCs into naïve 
pluripotency. In 2009, the addition of sodium butyrate, an inhibitor of histone 
deacetylase (HDAC), was reported to enable hPSC cultivation in the absence of 
bFGF. Female cells lose their XIST expression. These findings were shown only for 
one cell line, though. Other characteristics of naïve pluripotency were not reported 
(Ware et al., 2009). In another study, the application of LIF/2i conditions to hPSCs 
leads to the generation of primitive neural precursors instead of naïve PSCs (Li et al., 
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2011), which led to the speculation that mouse and human cells respond differently 
to LIF/2i. This could be the reason for the failure to derive naïve hPSC as until then 
the generation of a stable naïve human PSC line has not been achieved.  
Recently, Gafni et al. succeeded in generating stable human naïve pluripotent stem 
cells by modulating various signaling pathways. The starting cells are primed hPSCs.  
Addition of LIF, Tgf!1 and FGF2 and inhibition of ERK1/2, GSK3!, JNK and p38 
results in dome-shaped hPSC colonies. Next to the morphology, also the molecular 
characteristics such as X chromosome activation and the DNA methylation state 
reveal that their cell population represents naïve hPSCs. Furthermore, applying these 
conditions to embryos lead to successful generation of naïve hESCs from human 
blastocysts (Gafni et al., 2013). 
  
1.2.4 IL-6/sIL-6R fusion protein 
As mentioned before, hPSCs do not respond with an activation of Stat3 target genes 
upon LIF addition to standard cultures (Dahéron et al., 2004; Sato et al., 2004). The 
reasons for that are so far not known. One hypothesis is that LIF is not potent 
enough to activate Stat3 signaling in hPSCs (Amit et al., 2010). This hypothesis 
would suggest that a potent LIF agonist could induce Stat3 phosphorylation in 
hPSCs. One such possible agonist could be a chimeric fusion protein of Interleukin-6 
(IL-6) and its soluble receptor (sIL-6R), mainly consisting of the extracellular domain 
of the membrane bound IL-6R. Interleukin-6 is a cytokine that binds to the 
membrane-bound IL-6 receptor (IL-6R) and forms a heterodimer. This heterodimer 
induces to the dimerization of two gp130 and thereby activates Stat3 signaling. IL-6 
can also lead to trans-signaling when binding to the soluble form of its receptor. The 
mechanism of IL-6 transsignaling that occurs in vivo is shown in Figure 1.2. In case 
of the chimeric IL-6/sIL-6R protein, the ligand IL-6 is already bound to its soluble 
receptor, so that it just has to bind to membrane-bound gp130 to induce Stat3 
signaling. The signal-transducing transmembrane glycoprotein 130 is ubiquitously 
expressed, whereas not every cell type expresses the LIF receptor (LIFR) (Taga & 
Kishimoto, 1997). Contradictory reports about the expression of LIFR on hPSCs exist 
in the literature. While Rose-John published in 2002 that hESCs do not express 
LIFR, other groups showed LIFR expression (Chan et al., 2013; Humphrey et al., 
2004; Rose-John, 2002). If hPSCs do not express the LIF receptor or the Interleukin-
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6 receptor, the chimeric fusion protein nevertheless could induce Stat3 signaling in 
hPSCs. 
In 2010, Amit et al. showed that hPSCs can be cultivated in suspension when IL-
6/sIL-6R is added to the culture medium. Without the chimeric protein, the hPSCs 
tended to differentiate spontaneously into so called embryoid bodies, whereas in the 
presence of IL-6/sIL-6R the suspension cultures remained pluripotent (Amit et al., 
2010).  
 
Figure 1.2: Schematic function of IL-6 transsignaling in vivo 
To get a soluble IL-6 receptor (sIL-6R) either the membrane-bound IL-6R has to be shedded 
or the IL-6R mRNA has to be spliced alternatively. In the extracellular compartments, sIL-6R 
can bind to IL-6. The heterodimer can bind to membrane-bound gp130; its dimerization leads 
to active IL-6 signaling (Knüpfer & Preiss, 2008) 
 
1.3 Manipulation of hPSCs 
To gain insight into the molecular mechanisms of cellular processes, it is productive 
to perform (genetic) manipulation such as gain- or loss-of-function studies. 
Depending on the desired outcome, cells need to be manipulated either constitutively 
or transiently.  
 
 
 
Introduction 
 
! 12 
1.3.1 Transfection of DNA 
Nucleic acids can be transfected efficiently into cells via lipofection, electroporation or 
microinjection. Furthermore, cells can be infected with viral particles. When 
transfecting DNA, most commonly in form of a plasmid, there always is a risk of 
integration into the host genome (Wang et al., 2004). Transfected genes can be, 
depending on their promoter, constitutively active, making a control of transcription 
impossible. For that purpose, inducible systems have been established, for example 
the Tet/Dox system. In that case, the gene will only be transcribed when doxycycline 
is added (Baron, Gossen, & Bujard, 1997). Unfortunately, the Tet/Dox system is 
leaky, meaning that in some cases a background transcription can be detected 
(Hofmann, Nolan, & Blau, 1996). Furthermore, integration into the host genome can 
lead to frameshift mutations and therefore have undesired side effects, for example 
activation or silencing of genes (Strauss, 1999).  
Transfection of DNA into hPSCs is hard to achieve (Zwaka & Thomson, 2003). As 
the cells grow in tightly packed epithelial-like colonies, the cell surface presented to 
the environment is relatively small, thus the probability of the lipoplexes or viruses to 
attach to the cell is rather low (Van Hoof et al., 2008; Watanabe et al., 2007). When 
plated as single cells in the presence of a ROCK inhibitor, cells are stressed, and the 
DNA transfection, especially via viral transduction, leads to further stress. This results 
in a reduced survival of the cells and a poor outcome. The same problems occur 
when performing electroporation. Dissociation and electroporation lead to a high 
number of dead cells (Buecker et al., 2010). Thus, the establishment of an efficient 
transfection protocol of hPSCs is a critical step.  
 
1.3.2 Protein transduction 
To circumvent the disadvantages of DNA transfection, recombinant transducible 
forms of proteins have been developed. These transducible proteins consist of the 
protein of interest, which is linked to a protein transduction domain (PTD) and 
optionally to a nuclear localization signal (NLS) (Bosnali & Edenhofer, 2008; Dietz & 
Bähr, 2004; Peitz et al., 2002). The PTD is important to enable the cellular uptake of 
the protein. The PTD can be adapted from viral proteins, for example the commonly 
used TAT (transactivator of transcription)-domain that originates from the HI-virus 
(Frankel & Pabo, 1988; Green & Loewenstein, 1988; Nagahara et al., 1998). The 
NLS has to be fused to the protein of interest only if the protein needs to be 
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transferred to the nucleus and does not contain an internal NLS. In case of 
transcription factors, an NLS has not to be added, because they already posses an 
internal NLS (Pan et al., 2004). 
Transducible proteins can be applied to cell culture. The cells take up the protein in 
endosomes. If biologically active, the proteins will exert their effects until degraded.  
One disadvantage of transducible proteins is the detrimental effect to the cells. 
During purification, the protein has to be dialyzed into a buffer that keeps the protein 
stable. These buffers often contain substances that can stress the cells, e.g. glycerol. 
Due to the reduced half-life of proteins, transducible proteins usually have to be 
supplemented more than one time, resulting in repeated stress to the cells. However, 
the reduced half-life enables a control over the duration of the activity in the cell.  
Only a part of the added protein enters the cells, and only a fraction, around 1%, of 
the transduced protein, gets spontaneously released into the cytosol instead of 
remaining in endosomes (Jo et al., 2001; Peitz et al., 2002). Therefore, high 
concentrations of transducible protein have to be applied, making the purification 
cost-intensive and, furthermore, the application highly stressful to the cells. As 
described for DNA, hPSCs need to be singularized also for protein transduction. As 
in many cases protein has to be applied more than once, the growth of hPSCs in 
colonies raises a problem, as the tightly packed cells have a reduced surface 
presented to the protein. Protein transduction into hPSCs therefore is hard to 
achieve. 
 
1.3.3 Transfection of synthetic mRNA 
Recently, the transfection of synthetic mRNAs came to focus. It combines the 
advantages of DNA-transfection and protein transduction. mRNAs can be transfected 
into the cells with a high efficiency without the risk of integration into the host 
genome. Furthermore, mRNAs have a limited half-life making a control over the 
duration of activity in the cell possible.  
For the generation of synthetic mRNA, the open reading frame (ORF) of the gene of 
interest (goi) has to be fused to so-called untranslated regions (UTR). At the 5´ end, 
the UTR contains a strong Kozak sequence (Warren et al., 2010). At the 3´ end, an 
alpha-globin UTR is added which ends with an oligo(dT) sequence resulting in a 
polyA tail after transcription.  
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This construct of 5´UTR-ORF-3´UTR can be transcribed in vitro. In vitro-transcribed 
mRNA activates the innate immune system via binding to the TLR3 (Karikó et al., 
2004). In order to prevent innate immunity stimulation, the mRNA needs to be 
modified. The activation potential of RNA correlates inversely with the extent of their 
nucleoside modification (Karikó et al., 2005). Instead of using all four standard 
ribonucleosides, two modified ribonucleosides are used routinely. Instead of uridine, 
pseudouridine (psi) is added to the in vitro transcription (IVT) reaction, and 5-methyl 
cytidine (5mC) replaces cytidine. After the IVT, a 5´ Cap analog is added to the 
synthetic mRNA. The incorporation of 5mC and the addition of a 5´ Cap are typical 
features of mammalian mRNA, whereas pseudouridine is often found in ribosomal 
RNA (rRNA), with 80% the major constituent of cellular RNA (Bokar & Rottman, 
1998; Bachellerie & Cavaille, 1998). Taken together, these modifications make the 
synthetic mRNA resemble cellular mRNA more closely, and such modifications 
distinct intrinsic RNA from viral RNA, thus preventing immune reactions upon mRNA-
transfection (Warren et al., 2010). 
After the IVT and capping, the synthetic mRNA has to be purified and can be 
transfected via lipofection. The half-life of synthetic mRNA depends on the goi and is 
rather short with a maximum of expression 12 to 18 hours after transfection (Warren 
et al., 2010).    
In 2010, it was shown that synthetic mRNAs can be transfected into hPSCs; Warren 
et al. used synthetic mRNAs to induce differentiation in hiPSCs efficiently (Warren et 
al., 2010).  
 
1.3.4 Tools for genetic engineering 
One possible way to achieve genetic engineering is to use engineered nucleases. 
These nucleases cleave the DNA either on a random position, or on a specific target 
site (Sun, Abil, & Zhao, 2012). After cleaving the DNA, the DNA has to be repaired by 
the cell. This happens either by homology-dependent repair (HDR) or by non-
homologous end joining (NHEJ) (Jackson, 2002; Shiloh, 2003).  
In case of NHEJ, both sides of the double-strand brake are reconnected even if there 
is no sequence overlap. This repair mechanism can lead to errors in the genome 
(Seyffert, 2003). If foreign DNA shall be introduced, both cellular repair mechanisms 
NHEJ and HDR can be exploited. By introducing a donor DNA fragment with 
homology to the restricted genome, the foreign DNA can be incorporated into the 
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host genome via HDR. Donor DNA without homology to the cut host genome can be 
inserted spontaneously via NHEJ (Pan et al., 2013).  
One type of engineered nucleases are the Zinc Finger Nucleases (ZFNs). ZFNs can 
be engineered in that way that they bind to a specific DNA region and cut the 
targeted gene, inducing a double-strand break at the desired target to either 
inactivate the gene or to introduce foreign DNA (Kim, Cha, & Chandrasegaran, 1996; 
Miller et al., 2007).  
A disadvantage of the ZFN technology is that off-target effects can occur when the 
ZFN is not designed specifically enough. Off-target cleavage could lead to undesired 
genome editing (Gaj et al., 2012). The synthesis of specific ZFNs depends partly on 
chance, which makes it impracticable to design it in each lab. Routinely, ZFNs are 
designed by specialized companies. 
In 2009, hPSCs were engineered successfully using ZFN technology (Hockemeyer et 
al., 2009). Since 2010, a novel engineered nuclease called TALEN has gained 
impact on genome editing. Its modular structure and simple DNA binding code 
makes it highly specific and easy to design (Christian et al., 2010; Miller et al., 2011).  
 
1.3.5 TALENs as a novel tool for genetic manipulation of hPSC 
Transcription activator-like effector nucleases (TALENs) are proteins that consist of a 
DNA cleavage domain fused to a DNA binding domain. The DNA binding domain 
bases on the naturally occurring TALE proteins. TALEs are expressed by the plant 
pathogen Xanthomonas to undermine host genome regulatory networks (Boch & 
Bonas, 2010) For that, they specifically bind and regulate plant genes (Kay et al., 
2007). TALEs consist of a central repeat domain responsible for the DNA binding. 
Multiple of these so-called TALE repeats are arranged in tandem. The sequence of 
the 33-35 amino acids of each repeat unit are nearly identical, except for two 
adjacent amino acids that are highly variable. These two amino acids are called 
repeat variable di-residue (RVD) and are responsible for the target base recognition. 
A simple code shows which RVD targets which base (Boch et al., 2009). 
For genetic engineering, TALEs are fused to the cleavage domain of the FokI 
restriction enzyme resulting in a protein with nuclease activity (Cermak et al., 2011; 
Miller et al., 2011). To cleave the double-stranded DNA, two TALENs have to be 
designed. Both TALENs bind to two targeted sequences separated by 14 to 20 
bases. When both TALENs bind, their FokI catalytic domains dimerize and introduce 
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a double-strand brake (see Figure 1.3; Sanjana et al., 2012). As described for other 
engineered nucleases, the double-strand brake is repaired by the cellular repair 
mechanisms HDR or NHEJ.  
 
 
 
 
Figure 1.3: Scheme of TALEN binding and cleavage  
Schematic illustration of a TALEN pair. In the binding domain, each color represents a RVD 
that binds a specific base. The binding sites of both TALENs are in a distance of 14 to 20 
base pairs, were the catalytic FokI domains dimerize and cut the genome (Sanjana et al., 
2012) 
 
In 2011, Hockemeyer et al. transfected human pluripotent cells with plasmids 
encoding for TALENs. They succeeded in engineering hESCs as well as hiPSCs 
genetically (Hockemeyer et al., 2011a).  
 
1.4 Innate immunity 
The immune system is the system that protects an organism against diseases by 
recognizing foreign agents and pathogens and distinguishing them from host origin. 
In vertebrates, the immune system consists of two subtypes, the adaptive or acquired 
immune system and the innate immune system.  
The adaptive immune system creates an immunological memory. After a first contact 
to a pathogen, it creates a stronger immune response specific to this antigen. Instead 
of the adaptive immune system, which is only found in vertebrates, an innate immune 
system can be found also in invertebrates as well as in plants and prokaryotes as it is 
cell-autonomous and present in each cell. The innate immune system is the first line 
of defense against pathogens. It is non-specific and responds to pathogens in a 
generic way; therefore it is distinct to the adaptive immune system.  
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1.4.1 Innate immunity in somatic mammalian cells  
Mammalian cells are exposed to a variety of external threats. For example, an 
infection with a virus conveys nuclear acids into the cell. The cell then has to be able 
to distinguish between its own and pathogenic material. Responsible for the detection 
of and the defense against pathogenic substances is the innate immune system of 
the cell.  
The targets of the innate immune recognition are the so-called pathogen-associated 
molecular patterns (PAMPs). They are conserved molecular patterns, which are 
recognized by receptors of the innate immune system that are called pattern-
recognition receptors (PRR) (Meylan, Tschopp & Karin, 2006; Takeuchi & Akira, 
2010). There are many different PRRs; they can be expressed on the cell surface or 
in intracellular compartments. Furthermore, they can be secreted and therefore 
sense for microbial infections in blood or in tissue fluids (Medzhitov, 2001).  
PAMPs are constitutive and conserved products of the microbial metabolism, which 
are essential for the survival of microorganisms and do not occur in the host cells. 
The matter that they are essential for survival is important, as microorganisms tend to 
mutate frequently. Existential proteins will not mutate in a high frequency, as 
mutation could lead to cell death or at least to a reduced adaptive fitness (Medzhitov, 
2001). 
The major type of PRRs consists of the so-called Toll-like receptors (TLRs). They 
have two characterizing domains: extracellular it is a leucine-rich repeat (LRR) 
domain and intracellular a Toll/IL-1 receptor (TIR) domain. The LRR domain is 
responsible for ligand recognition, whereas the TIR domain is essential for protein-
protein interactions (Hashimoto et al., 1988; Medzhitov, Preston-Hurlburt, & 
Janeway, 1997).  
The different members of the TLR family recognize different PAMPs. For example, 
TLR3 is responsible for recognition of dsRNA. TLR3 is found both on cell surface and 
endosomes (Matsumoto et al., 2002). After TLR3 recognizes dsRNA, it recruits TRIF 
to endosomes, which there functions as a docking platform that interacts with several 
signaling proteins to activate NF"B, IRF3 and IFN! (Jiang et al., 2004). 
Another important player in the response to dsRNA infection is PKR (dsRNA-
activated protein kinase) (McAllister & Samuel, 2009). It is directly activated by 
dsRNA (Lemaire et al., 2008). Upon activation, several substrates, such as I"B, are 
phosphorylated. This leads to an activation of different target genes, for example 
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IFN! (Kumar & Carmichael, 1998). PKR does not only activate the transcription of 
the genes important for immune response, but also limits viral replication by inhibiting 
the proliferation of the host cell (García, Meurs, & Esteban, 2007). 
 
1.4.2 Immunity during human development 
The developing embryo has basically no immunity. It develops in the sterile 
environment of the womb and therefore is, when no infections occur, not exposed to 
pathogens to that it could adapt immunity. In the fetal stage, immunoglobulins of the 
IgG class are transferred from the mother to the fetus (Saji et al., 1999). This so 
called passive immunity protects the newborn against pathogens the mother adapted 
immune response against. However, the IgGs are degraded and therefore protect the 
newborn only for a limited time (Hinton et al., 2006).  
The innate immune system does not require exposure to pathogens. Nonetheless, 
TLR responses in the embryo develop relatively late and are suppressed in the 
neonatal period (Levy, 2007). In the first trimester of pregnancy, cells of different 
tissues of the placenta express TLRs (Holmlund et al., 2002). TLR2 is activated 
through its ligand Peptidoglycan upon infection with gram-positive bacteria in 
trophoblasts. But instead of cytokine secretion, it induces apoptosis (Abrahams & 
Mor, 2004). Accumulated apoptosis in the placenta leads to abnormal pregnancy 
outcomes as abortions and preterm births (Jerzak & Bischof, 2002).  
Taken together, these data suggest that the placenta is responsible for the protection 
of the embryo against pathogens. The embryo itself seems not to have an innate 
immune system.  
 
1.4.3 Innate immunity in PSCs 
An interesting feature of pluripotent stem cells is their proposed attenuated capacity 
to react on the infection with viral RNA.  
Chen et al. showed in 2010 that in hESCs and hiPSCs transfection with dsRNA did 
not lead to an activation of IFN! expression. hPSCs do express the dsRNA-activated 
protein kinase (PKR) and some of its downstream signaling targets like I"B, NF"B 
and IRF3, but PKR is not phosphorylated and thus activated. Strikingly, hPSCs do 
not express TLR3. However, after 4 days of BMP4-induced differentiation into 
trophoblasts, IFN! induction was enhanced 10fold (Chen, Yang, & Carmichael, 
2010). 
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These results stand in conflict with results published also in 2010. It was reported 
that H7 hESCs express TLR3 at a similar level as adult human endothelial cells, 
whereas TLR1, 4 and 6 are expressed less. TLR8 and 10 are not expressed at all, 
but TLR5 is expressed at an even higher level. The expression levels of NF"B- and 
TLR signaling genes are comparable to the adult endothelial cells. Furthermore it 
was reported that, upon PAMP stimulation, hESCs do not release CXCL8, which act 
as a biomarker for cell activation in that study. Remarkably, cells that were 
differentiated for up to 4 months into endothelial cells do not react with CXCL8 
release to PAMP stimulation. Only IL-1!, which acts independently of TLRs, induces 
CXCL8 secretion (Földes et al., 2010). 
In another report, prolonged differentiation leads to increased innate immunity. 
Differentiation of hESC-derived neurons into hESC-derived neural precursor cells 
(NPCs) increases the expression of the IFN type I signaling pathway components 
IRF-9 and IFNAR2. Therefore, differentiation leads to an increased protection against 
viral infections (Farmer et al., 2013). 
For murine PSCs, it was also reported that they posses a low immunogenic potential. 
In 2006, it was published that mESCs as well as cells differentiated from ESCs 
(endothelial cells (esECs) and smooth muscle cells (esSMCs)) do not react with 
cytokine release upon LPS treatment. mESCs as well as esECs and esSMCs do not 
express TLR4 (Zampetaki et al., 2006).  
Viruses can infect mPSCs of the D3 line and exert their cytopathic effects, but the 
cells do not express type I IFNs as a response to that. Furthermore it was shown that 
mESCs express TLR3 only at a very low level compared to fibroblasts (Wang et al., 
2013). Conflicting with these two publications, another study investigating the role of 
TLRs in mPSCs reported that murine ESCs as well as adult stem cells express 
functional TLRs. Their activation even leads to an increased proliferation (Lee et al., 
2009). 
Overall, innate immunity of PSCs still is poorly understood, making it an interesting 
field of research. In case of a possible future use in regenerative medicine, the 
immunogenic potential of the cells need to be elucidated. When differentiating 
transplant cells from hPSCs, it has to be clarified whether the cells acquire an innate 
immunity; otherwise, transplanted cells would be amenable to viral infections and 
thus a risk for the host.  
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1.5 Aim of the Thesis 
Aim of this thesis is to analyze two different aspects of the biology of human 
pluripotent stem cells (hPSCs). 
 
First of all the role of Stat3 signaling in hPSCs shall be analyzed. With a potent LIF 
agonist, an IL-6/sIL-6R chimeric fusion protein, the signaling shall be activated in 
hPSCs, cells that usually do not respond to LIF.  
Initially, it shall be determined if the chimeric protein is feasible to maintain 
pluripotency in hPSCs in the absence of feeder cells.  
Further it shall be investigated whether it is possible to activate Stat3 in hPSCs. Via 
immunoblot it shall be shown whether Stat3 is getting phosphorylated. Expression of 
putative target genes of the Stat3 signaling shall be shown with qRT-PCR.  
To further investigate the role of Stat3-signaling, a robust genetic loss-of-function 
model shall be established. For that TALEN technology shall be used. To gain a high 
efficiency, an mRNA encoding for TALEN that target Stat3 shall be synthesized.  
In order to improve mRNA transfection efficiency, different synthetic mRNAs will be 
tested. Preliminary data of other groups let assume that hPSCs could be transfected 
with unmodified synthetic mRNA.  
Because of that the immune response of hPSCs is another general aspect of stem 
cell biology, which will be investigated in this thesis.  
It will be examined whether hPSCs can be transfected efficiently with unmodified 
synthetic mRNA. For that, an mRNA encoding for GFP will be used. Efficiencies will 
be estimated via flow cytometry. The activation of the innate immune system upon 
transfection with modified and unmodified synthetic mRNA shall be shown by using 
qRT-PCR.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals used are obtained from Sigma-Aldrich GmbH (Steinheim, Germany), 
Carl Roth GmbH (Karlsruhe, Germany), Merck (Darmstadt, Germany), Life 
Technologies (Darmstadt, Germany) and Fluka (Bad Homburg, Germany). 
In general, solutions are prepared using water from a Millipore filter system (Millipore, 
Eschborn, Germany). 
 
2.1.2 Equipment 
Table 2.1: Technical equipment 
Appliance Name Manufacturer 
Autoclave D-150 Systec (Wettenberg, Germany) 
Bacterial shaker  New Brunswick Scientific 
(Nürtingen, Germany) 
Block heater Thermomixer compact Eppendorf (Hamburg, Germany) 
Cell culture centrifuge Megafuge 1.0R Heraeus (Hanau, Germany) 
Centrifuge RC5B plus Thermo (Waltham, USA) 
Chemiluminescence 
detection 
Chemidoc XRS Biometra (Göttingen, Germany) 
Counting chamber Fuchs-Rosenthal Faust (Halle, Germany) 
Digital camera Canon Power Shot G5 Canon (Krefeld, Germany) 
Flow Cytometer FACS Calibur BD (Mountainview, USA) 
Fluorescence cam DFC345 FX Leica (Wetzlar, Germany) 
Fluorescence lamp  Leica (Wetzlar, Germany) 
Fluorescence microscope DMIL LED Fluo Leica (Wetzlar, Germany) 
Freezing container “Mr.Frosty” 5100 Cryo Nalgene (Roskilde, Denmark) 
Gel electrophoresis 
chamber 
Agagel Biometra (Göttingen, Germany) 
Gel Documentation Geldoc2000 Biorad (Munich, Germany) 
Incubator (Cell culture) HERAcell 150 Heraeus (Hanau, Germany) 
Inverse light microscope Axiovert 40C Carl Zeiss (Jena, Germany) 
Liquid nitrogen store MVE 611 Chart Industries (Burnsville, USA) 
Magnetic stirrer  Stuart Scientific (Staffordshire, UK) 
Micropipette 2#l, 10#l, 100#l, 1000#l Eppendorf (Hamburg, Germany) 
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Micro-Spectrophotometer Nanodrop ND-1000 Peqlab (Erlangen, Germany) 
pH-meter CG840 Schott (Mainz, Germany) 
Pipetteboy Accu-Jet II Brand (Wertheim, Germany) 
Powersupply for agarose 
electrophoresis 
Standard Power Pack 
P25 
Biometra (Göttingen, Germany) 
Refrigerator 4°C/-20°C G 2013 Comfort Liebherr (Lindau, Germany) 
Refrigerator -80°C HERAfreeze Heraeus (Hanau, Germany) 
Scales LA310S; BL610 Sattorius (Göttingen, Germany) 
SDS-PAGE system ProteanIII MiniGel 
System 
Biorad (Munich, Germany) 
Sterile laminar flow hood HERAsafe Heraeus (Hanau, Germany) 
Table centrifuge Centrifuge 5415R Eppendorf (Hamburg, Germany) 
Thermocycler T3000 Biometra (Göttingen, Germany) 
UV transilluminator GelVue GVM20 Syngene (Cambridge, UK) 
Vacuum pump Vacuubrand Brand (Wertheim, Germany) 
Vortexer Genie 2 Scientific Industries (Bohemia, 
USA) 
Water bath 1008 GFL (Burgwedel, Germany) 
 
 
2.1.3 Disposables 
Table 2.2: Disposables 
Disposable Manufacturer 
Adhesive PCR films Peqlab (Erlangen, Germany) 
Centrifuge tubes Corning (Kaiserslautern, Germany) 
Cryovials Nunc (Wiesbaden, Germany) 
“Whatman” filter papers GE Healthcare Biosciences (Pittsburgh, USA) 
Nitrocellulose membrane Carl Roth GmbH (Karlsruhe, Germany) 
Parafilm Pechinery (Chicago, USA) 
PCR plate (96 well) Peqlab (Erlangen, Germany) 
PCR stripe tubes 0.2ml Peqlab (Erlangen, Germany) 
Reaction tubes (1ml, 1.5ml) Eppendorf (Hamburg, Germany) 
Serological pipettes (5ml, 10ml, 25ml) Corning (Bodenheim, Germany) 
Syringe filter 0.2#m Millipore (Schwalbach, Germany) 
Syringes BD Biosciences (Heidelberg, Germany) 
 
Tissue Culture dishes 
BD Biosciences (Heidelberg, Germany) 
Corning (Kaiserslautern, Germany) 
Nunc (Wiesbaden, Germany) 
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Disposables used for cell culture are either delivered as sterile material or autoclaved 
prior to use.  
 
 
2.1.4 Enzymes 
Table 2.3: Enzymes 
Enzyme Manufacturer 
Phusion Taq polymerase NEB (Frankfurt, Germany 
Proteinase K Sigma-Aldrich (Steinheim, Germany) 
Restriction endonucleases  Thermo Scientific (Dreieich, Germany) 
T7 endonuclease I NEB (Frankfurt, Germany) 
  
 
 
2.1.5 Antibodies 
Table 2.4: Antibodies 
Antibody Dilution Manufacturer 
anti beta-actin 1:800 EMD Millipore (San Diego, USA) 
Monoclonal anti-FLAG® M2 
antibody produced in mouse 
1:400 Sigma (Steinheim, Germany) 
anti pStat3 (Tyr 705) rabbit 1:500 Cell Signaling Technology (Boston, USA) 
anti Stat3 rabbit 1:500 Cell Signaling Technology (Boston, USA) 
anti-Mouse IgG, HRP-linked 
antibody 
1:1000 Cell Signaling Technology (Boston, USA) 
anti-Mouse IgG, HRP-linked 
antibody 
1:1000 Cell Signaling Technology (Boston, USA) 
   
 
2.1.6 Kits 
Table 2.5: Kits 
Kit Manufacturer 
AmpliScribe™ T7-Flash™ Transcription Kit Epicentre (Madison, USA) 
DryEase® Life Technologies (Karlsruhe, Germany) 
GoTaq Flexi DNA polymerase Kit Promega (Mannheim, Germany) 
iScript™ Reverse Transcription Kit Biorad (Munich, Germany) 
Lipofectamine ®LTX Transfection Kit Life Technologies (Karlsruhe, Germany) 
NucleoBond® Xtra Midi/Maxi Kit Macherey-Nagel (Düren, Germany) 
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Nucleospin RNA II Macherey-Nagel (Düren, Germany) 
PathScan® Phospho-Stat3 (Tyr705) 
Sandwich ELISA Kit 
Cell Signaling Technology (Boston, USA) 
ScriptCap™ m7G Capping System Cellscript (Madison, USA) 
ScriptCap™ 2´-O-Methyltransferase Kit Cellscript (Madison, USA) 
SuperSignal™ West Femto Substrate Kit Thermo Scientific (Dreieich, Germany) 
SuperSignal™ West Pico Substrate Kit Thermo Scientific (Dreieich, Germany) 
TransIT® RNA Transfection Kit Mirus Bio LLC (Madison, USA) 
Wizard® SV Gel and PCR Clean-Up System Promega (Madison, USA) 
  
 
 
2.1.7 Markers 
Table 2.6: Markers and ladders 
Marker Manufacturer 
1kb DNA ladder NEB (Frankfurt, Germany) 
1000bp DNA ladder NEB (Frankfurt, Germany) 
Prestained Protein Marker NEB (Frankfurt, Germany) 
ssRNA ladder NEB (Frankfurt, Germany) 
  
 
 
 
2.1.8 Cell lines and bacterial strains 
 
CRL-2097 (ATCC; Manassas, USA) 
CRL-2097 cells are human foreskin fibroblasts obtained from a male Caucasian. 
CRL-2097 are kept in culture until passages around 20, in higher passages they lose 
their replication potential.  
 
DH5$ (Life Technologies; Karlsruhe, Germany) 
DH5$ bacteria cells are used for amplification of plasmid DNA. They posses a high 
transformation efficiency. 
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DravetFB 
Dravet fibroblasts are primary fibroblasts. They were obtained from a Dravet patient 
through a skin biopsy (kindly provided by Johannes Jungverdorben, Institute for 
Reconstructive Neurobiology, University of Bonn).  
 
E14T 
E14T is a murine embryonic stem cell line.  
 
H9.2  
H9.2 are wildtypic human embryonic stem cells from Haifa, Israel and were 
generated in 2000 (Amit et al., 2000). 
 
HEK 293T (Invitrogen, Karlsruhe, Germany) 
HEK 293T is an immortalized human cell line extracted from the kidney (Human 
embryonic kidney cells). They have a modal chromosome number of 64. Usually they 
are used for the production of lentiviral particles. In this thesis they are used as 
control cells. 
  
HepG2 
HepG2 is a human liver carcinoma cell line that is a suitable model for human 
hepatocytes. In this thesis they are used to test the functionality of the IL-6/sIL-6R 
fusion protein. HepG2 cells are known to have a functional Stat3 signaling upon 
stimulation. HepG2 cells were kindly provided by Ines Raschke (Life and Medical 
Sciences Institute, University of Bonn). 
 
I3 
I3 is a wildtypic human embryonic stem cell line derived from the inner cell mass of a 
blastocyst (Amit & Itskovitz-Eldor, 2002).   
 
iLB-30-r12 
The iPSC line iLB-30-r12 was generated in our lab by Johannes Jungverdorben 
(unpublished) using the four classical reprogramming factors Oct4, Sox2, Klf4 and c-
Myc. They are characterized as bona fide iPS cells exhibiting all characteristics of 
hPSCs.  
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lt-NES cells 
lt-NES cells are human neural stem cells differentiated from hPSCs. The lt-NES cells 
examined in this thesis were differentiated from the iPSC line iLB-30-r12 by 
Johannes Jungverdorben (unpublished) using the protocol published by Li et al. 
(2011).  
 
2.1.9 Cell culture stock solutions 
Table 2.7: Cell culture stock solutions 
Stock Solution Manufacturer 
!-mercaptoethanol (50mM) Life Technologies (Karlsruhe, Germany) 
B27 Supplement (50x) Life Technologies (Karlsruhe, Germany) 
Basic FGF (bFGF; FGF-2) Life Technologies (Karlsruhe, Germany) 
Defined Trypsin Inhibitor Life Technologies (Karlsruhe, Germany) 
Dimethyl sulfoxide (DMSO) Life Technologies (Karlsruhe, Germany) 
DMEM/F-12 Life Technologies (Karlsruhe, Germany) 
DMEM high glucose Life Technologies (Karlsruhe, Germany) 
D-PBS Life Technologies (Karlsruhe, Germany) 
0.5mM EDTA/PBS Life Technologies (Karlsruhe, Germany) 
EGF  Life Technologies (Karlsruhe, Germany) 
ESGRO LIF (1000U/#l) EMD Millipore (San Diego, USA) 
Fetal Calf Serum (FCS); heat-inactivated Life Technologies (Karlsruhe, Germany) 
Glucose (4.5g/ml in DMEM/F-12) Carl Roth (Karlsruhe, Germany) 
GlutaMAX (100x) Life Technologies (Karlsruhe, Germany) 
hLIF (10#g/ml) EMD Millipore (Billerica, USA) 
KnockOut DMEM Life Technologies (Karlsruhe, Germany) 
KnockOut Serum Replacement Life Technologies (Karlsruhe, Germany) 
Laminin (natural mouse) Life Technologies (Karlsruhe, Germany) 
Matrigel™ hESC qualified matrix BD Biosciences (Heidelberg, Germany) 
mTeSR™-1 StemCell Technologies (Grenoble, France) 
N2 Supplement (100x) Life Technologies (Karlsruhe, Germany) 
Non-Essential Amino Acids (NEAA; 100x) Life Technologies (Karlsruhe, Germany) 
OptiMEM Life Technologies (Karlsruhe, Germany) 
Sodium Pyruvat Life Technologies (Karlsruhe, Germany) 
2.5% Trypsin (10x) Life Technologies (Karlsruhe, Germany) 
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2.1.10 Inhibitors and small molecules 
Table 2.8: Inhibitors and small molecules 
Name Inhibitor of Manufacturer 
B18R IFN signaling eBioscience (San Diego, USA) 
CHIR GSK3 EMD Millipore (San Diego, USA) 
HALT protease inhibitor proteases Thermo Scientific (Dreieich, Germany) 
IL-6/sIL-6R  Merck (Darmstadt, Germany) 
Y-27632 ROCK EMD Millipore (San Diego, USA) 
   
The IL-6/sIL-6R fusion protein is not available commercially.  
 
2.1.11 Oligonucleotide primers 
All oligonucleotides are displayed in 5´ to 3´ direction. 
Table 2.9: Primers used for qRT-PCR 
Primer Sequence 
GAPDH fwd GAGTCAACGGATTTGGTCGT 
GAPDH rev GACAAGCTTCCCGTTCTCAG 
IFN! fwd CAGCATCTGCTGGTTGAAGA 
IFN! rev CATTACCTGAAGGCCAAGGA 
Pim1 fwd GCCCTCCTTTGAAGAAATCC 
Pim1 rev GGACCTGGAGTCTGGAATGA 
Socs3 fwd TCAAGGGACACGCCTTCTGA 
Socs3 rev TGTAAACCTCGAGGTGGAAG 
  
All primers used for qRT-PCR are designed to have an annealing temperature of 
60°C. 
 
Table 2.10: Primers used for T7-Assay 
Primer Sequence 
Stat3 target fwd ATGCTCACGGGTAAGTATACAGAGC 
Stat3 target rev CTAGGGCATATGCGGCCAGC 
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Table 2.11: Primers used for the generation of IVT templates 
Primer Sequence 
5´UTR fwd TTGGACCCTCGTACAGAAGCTAATACG 
3´UTR rev GCGTCGACACTAGTTCTAGACCCTCA 
3´TailT rev T120CTTCCTACTCAGGCTTTATTCAAAGACCA 
  
 
2.1.12 Software 
Table 2.12: Software 
Name Application Producer 
CellQuest Pro Flow cytometry data acquisition BD  
FlowJo 8.7 Flow cytometry data analysis Tree Star, Inc. 
iCycler analysis software qRT-PCR analysis Bio-Rad 
ImageJ 10.2 Densiometric analysis NIH 
Microsoft Office 2007 Figure- and text processing Microsoft 
Quantity One 4.6.3 Electrophoresis gel documentation Bio-Rad 
Photoshop CS3 Image processing Adobe 
   
 
2.2 DNA 
2.2.1 Transformation of E.coli 
An aliquot of 100 #l of competent E.coli cells (strain: DH5$) is thawn on ice. Once 
thawed, 10 ng of the plasmid to be amplified is added to the cells following incubation 
for 30 minutes on ice. Subsequent to a heat shock at 42°C the cells are incubated on 
ice for another 2 minutes. 900 #l of SOC medium are added, the solution is incubated 
for 1 hour at 37°C while shaking in a thermo shaker devise. The transformed E.coli 
can be used for inoculation of an overnight culture for plasmid preparation.  
 
2.2.2 Preparation of DNA 
An overnight culture of 250 ml LB medium containing 250 #l ampicillin (final 
concentration 0.1 mg/ml) is inoculated with transformed E.coli of the strain DH5$. 
The beaker containing the solution is incubated overnight at 37°C at 120 rpm in a 
bacterial shaker. The next day, the cells are pelleted by centrifugation for 10 minutes 
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at 4000 rpm at 4°C. Plasmid DNA is extracted using the NucleoBond® Xtra Midi / 
Maxi Kit (Macherey-Nagel) following the manufacturers protocol.  
The plasmid DNA is resuspended in 100 #l nuclease-free H2O. 
 
2.2.3 Sodium Acetate precipitation of DNA 
In order to get DNA into another buffer or to concentrate it, it can be precipitated. 
First, 1/10 volume of 3M sodium acetate (pH 5.2) is added to the aqueous DNA 
solution followed by 2.5 volumes of 100% ethanol. After mixing by inverting the 
reaction tube, the solution is incubated for 5 minutes on ice. Subsequently, the 
precipitate is centrifuged for 30 minutes at 16 000 rpm at 4°C. The resulting pellet is 
washed twice with 70% ethanol, each followed by a centrifugation for 15 minutes at 
16 000 rpm, 4°C. The DNA pellet is dried and recovered in an appropriate volume of 
the desired buffer or water.  
 
2.2.4 Quantification of DNA 
The concentrations of DNA solutions are determined using the NanoDrop system 
(PeqLab). This system measures the absorption at a wavelength of 260 nm, the 
wavelength at which nucleic acids posses their maximum absorption. Furthermore it 
measures the absorption at a wavelength of 280 nm as proteins that naturally contain 
aromatic amino acids absorb at 280 nm. Therefore the ratio of the optical densities 
(OD 260/280) defines the purity of the DNA. A ratio of >1,8 is desirable for further 
applications.  
 
2.2.5 Restriction Hydrolysis for TALEN-mRNA synthesis 
In order to prepare synthetic TALEN-mRNA, it is necessary to have templates in the 
form of 5´UTR-TALEN-3´UTR. The TALEN plasmids are designed in that way that a 
simple restriction hydrolysis with 2 enzymes, namely Bsp120I and HindIII, results in a 
fragment containing the desired structures. For further procedures, a high number of 
templates are needed; so 10 #g of plasmid DNA was digested.  
Therefore, a double digest is performed using the following protocol: 
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10 #g DNA 
5 #l Tango Buffer  
1 #l Bsp120I 
1 #l HindIII 
x #l H2O (adjust to 50#l) 
 
Digestion is performed for 2 hours at 37°C. Afterwards, the enzymes are heat-
inactivated for 20 minutes at 80°C. 
The obtained fragments can be separated using agarose gel electrophoresis; the 
fragment to be worked with can be cut out and purified as described in 2.2.7.  
 
2.2.6 Agarose gel electrophoresis 
DNA fragments can be separated according to their size by using gel 
electrophoresis. For that, an electric field is applied to a chamber that holds an 
agarose gel loaded with DNA samples. Due to the negative charge of the phosphate 
backbone of the DNA, the fragments move towards the anode with a velocity that is 
inverse proportional to the logarithm of the fragments molecular weight.  
To visualize the DNA fragments, a fluorescing dye is added to the gel. This dye, 
ethidium bromide, intercalates to nucleic acids. It can be visualized with short-wave 
UV light.  
For preparation, agarose is diluted in TAE Buffer at a concentration of 1-2% (w/v) 
and shortly boiled in the microwave until the agarose powder is dissolved. After 
cooling down, ethidium bromide is added 1:10 000, resulting in a concentration of 1 
#g/ml; the gel solution immediately is poured into a gel chamber with a slot comb. 
Once solidified, the gel is transferred into a gel electrophoresis chamber and loaded 
with the samples. To picture its running front, the samples are mixed 1:10 with 10x 
Agarose Gel Loading Buffer. To estimate the size of the DNA fragments, at least one 
slot is loaded with a DNA ladder. 
After loading the samples to the gel, an electric field with a voltage of 60-120 Volts is 
applied for 30 to 60 minutes, depending on the size of the fragments. Visualization 
and documentation can be performed in the GelDoc system (Biorad, Munich, 
Germany).  
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TAE Buffer: 40mM Tris 
 20mM Acetic acid 
 1mM EDTA 
 pH of 50xTAE has to be adjusted to 8.4 
 
 
10x Agarose Gel Loading Buffer: 30% Glycerin 
 spatula tip of bromphenol blue 
 spatula tip of xylenxyanol 
 
2.2.7 Purification of DNA from agarose gels  
DNA can be purified from agarose gels or PCR reactions using the Wizard® SV Gel 
and PCR Clean Up System (Promega).  
When planning to extract DNA from an agarose gel, low melting agarose is used for 
electrophoresis. After running the gel as described before, DNA can be visualized 
with UV light and the desired band can be cut out with a scalpel. Extraction is 
performed according to manufacturers protocol. 
 
2.2.8 Quantitative reverse transcriptase polymerase chain reaction 
Quantitative reverse transcriptase PCR (qRT-PCR) is a method to determine the 
concentration of a given cDNA molecule. As a first step, RNA is isolated from the 
cells of interest as described in 2.3.1. Subsequently, the RNA is treated with DNase 
to remove any genomic DNA and then reverse transcribed into cDNA using the 
iScript Kit (Biorad) according to manufacturers instructions.  
2 #g of RNA are used for the reverse transcriptase reaction. The obtained cDNA is 
diluted 1:5 before using it for qRT-PCR. 
 
Reaction Mix: 
1 #l cDNA (diluted 1:5) 
1 #l Primer Mix 
10.375 #l H2O 
12.5 #l qRT-PCR Supermix 
0.125 #l GoTaq Flexi DNA polymerase 
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qRT-PCR Supermix: 1511.5 #l H2O 
 2000 #l 5x GoTaq Flexi Buffer 
 1000 #l MgCl2 
 80 #l 100mM dNTP (20#l each)  
 400 #l DMSO 
 1 #l 100#M Fluorescin 
 7.5 #l 1000x SYBR green 
 
The qRT-PCR reaction is performed in the iCycler with the following cycle 
parameters: 
1. 95°C 5 min 
2. 95°C 60 sec 
3. 60°C 60 sec 
4. 72°C 40 sec 
5. 72°C 5 min 
      Steps 2-4 were repeated 40 times. 
 
qRT-PCRs are done in triplicates. Expression levels get normalized to GAPDH 
expression. 
 
2.2.9 T7-Assay 
To determine the functionality of TALEN pairs, a T7-assay can be performed. This 
assay makes use of the T7 endonuclease I, an endonuclease derived from the T7 
bacteriophage. The T7 endonuclease I recognizes and cleaves non-perfectly 
matched DNA. After genomic engineering with TALENs, the restricted DNA is ligated 
via nonhomologous end-joining (NHEJ) or homology-dependent repair (HDR). To 
test whether a TALEN pair has engineered the genome, cells are lysed two days 
after transfection in lysis buffer. The reactions are incubated at 65°C for 10 minutes 
and subsequently at 95°C for 15 minutes. 1#l of the lysate is used for a 25 #l PCR 
reaction using Phusion Taq-Polymerase according to manufacturers protocol. 
Primers were chosen to amplify a 300-400bp-sized fragment containing the target 
side of the TALEN. In case of the Stat3 TALEN pair used in this thesis, the primers 
Stat3 target fwd and Stat3 target rev are used.  
 
 
Materials and Methods 
 
!33 
 
        Steps 2-4 were repeated 32 times.  
 
5#l of the reaction are mixed with 1.1 #l 10x NEB buffer 2 and 4.4 #l H2O. After 
heating to 95°C, the reaction is cooled down at a ramp rate of 0.7°C per minute. After 
reaching room temperature, 0.5 #l of T7 endonuclease I are added, the reaction is 
incubated at 37°C for 20 minutes. Subsequently, reaction can be, mixed with 10x 
Agarose Gel Loading Buffer, separated on a 2% agarose gel at 100V. Densiometric 
quantification of DNA bands are performed using ImageJ. Mutation frequencies can 
be calculated using the formula:  
 
fractional modification= 1 – (1 – (fraction cleaved))0.5  (Miller et al., 2007) 
 
Lysis Buffer: 0.2 #g/ml proteinase K 
 1mM CaCl2 
 3mM MgCl2 
 1mM EDTA 
 1% Triton X100 
 10mM Tris pH 7.5 
 
2.3 RNA 
2.3.1 Purification of RNA 
In order to get RNA for qRT-PCR, cells get detached and centrifuged. The pellet is 
washed once with PBS. Subsequently, RNA is isolated using the Nucleospin RNA II 
kit (Macherey-Nagel). 
To get purified RNA after in vitro transcriptions, the same kit can be used, following 
the “PCR clean up”-protocol. 
Both procedures are carried out according to manufacturers instructions.  
PCR program:     1. 98°C 30 sec 
2. 98°C 30 sec 
3. 64°C 30 sec 
4. 72°C 15 sec 
5. 72°C 10 min 
6.   4°C Hold 
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2.3.2 Quantification of RNA 
The concentrations of RNA solutions can be determined using the NanoDrop system 
(PeqLab). This system measures the absorption at a wavelength of 260 nm, the 
wavelength at which nucleic acids posses their maximum absorption. Furthermore it 
measures the absorption at a wavelength of 280 nm as proteins that naturally contain 
aromatic amino acids absorb at 280 nm. Therefore the ratio of the optical densities 
(OD260/280) defines the purity of the RNA. A ratio of >1,8 is desirable for further 
applications.  
 
2.3.3 Generation of templates for synthetic mRNA 
To generate synthetic mRNA, a template is needed which consists of the open 
reading frame (ORF) of the gene of interest, flanked by the so-called untranslated 
regions (UTR) important for the following in vitro transcription (IVT). So-called splint 
oligonucleotides, short primers that bind to the ends of the ORF and to the UTR, 
mediate the ligation of these UTRs to the ORF. Both GFP (Dominic Seiferling, 
unpublished) and TALEN (kindly provided by Tobias Schmidt) constructs were 
cloned in our lab and by the Hornung Lab in a plasmid in that way that they were 
already flanked by UTR. So UTR ligation can be skipped. As an overview for 
template generation, a scheme is depicted in Figure 2.1. 
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Figure 2.1: Schematic overview of template generation (modified after Warren et al., 
2010) 
The steps “ORF PCR” and “UTR ligation” could be skipped. Red:open reading frame of the 
gene of interest; green: UTR, yellow: polyA tail 
 
 
Template PCR 
As a first step, the template needs to be amplified using special primers that bind to 
the UTR, meaning that for every template the same primers could be used. 
 
Reaction Mix: 
10 #l 5x HF Buffer 
1 #l dNTP 
1 #l 5´UTR fwd 
1 #l 3´UTR rev 
10 #l DNA 
0.2 #l Phusion Taq-Polymerase 
36.8 #l H2O 
In case of the TALEN constructs, 1.5 #l of H2O are replaced with 1.5 #l of DMSO in 
order to improve the outcome of the PCR, as the DNA fragment to be amplified is 
comparatively long. 
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      Steps 2 – 4 were repeated 35 times. 
 
 
Whether the reaction results in a template of the expected size is tested using gel 
electrophoresis. Afterwards, DNA is extracted from the gel as described before.  
 
Tail PCR 
In order to get synthetic mRNA with a polyA tail, as a next step a polyA tail have to 
be added to the template. For that, a special primer (3´TailT rev) is used with a 120 
nucleotide long T-stretch. The primers used for the tail PCR bind at the UTR, so that 
again for each template the same primers can be used.  
 
Reaction Mix:           40 #l 5x HF Buffer 
6 #l DMSO 
2 #l dNTP 
2 #l 5´UTR fwd 
2 #l 3´TailT rev 
4 #l DNA 
4 #l Polymerase 
144 #l H2O 
 
        Steps 2 – 4 were repeated 35 times. 
PCR program:    1.  98°C 30 sec 
2.  98°C 30 sec 
3.  58°C 30 sec 
4.  72°C 1 min (GFP)/1:45 min (TALEN) 
5.  72°C 10 min 
6.    4°C Hold 
PCR program:     1. 98°C 30 sec 
2. 98°C 30 sec 
3. 58°C 30 sec 
4. 72°C 1 min (GFP)/ 1:45 min (TALEN) 
5. 72°C 10 min 
6.   4°C Hold 
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Afterwards, the tailed template gets precipitated with Sodium Acetate as described in 
2.2.3. The pellet is recovered in 5 #l H2O, resulting in a high DNA-concentration of 
>1#g/#l, which is important for the following In Vitro Transcription. 
 
2.3.4 Generation of synthetic mRNA 
In Vitro Transcription 
For the In Vitro Transcription (IVT) reactions the AmpliScribe™T7-Flash™ 
Transcription Kit (Epicentre) is used. The IVT reaction is driven by a T7 promotor 
within the 5´UTR.  
 
Reaction mix: 
1 #g Template DNA 
2 #l AmpliScribe T7-Flash 10x Reaction Buffer 
1.8 #l 100mM ATP 
1.8 #l 100mM CTP or Methyl-CTP 
1.8 #l 100mM GTP 
1.8 #l 100mM UTP or Pseudo-UTP 
2 #l 100mM DTT 
0.5 #l RiboGuard RNase Inhibitor 
2 #l AmpliScribe T7-Flash Enzyme Solution 
X #l H2O (adjust to 20 #l) 
 
The IVT reaction mix gets incubated for 45 minutes at 37°C (GFP mRNA) or 60 
minutes at 42°C (TALEN mRNA) respectively. According to the manufacturers 
protocol, the enzymes have an activity range for temperatures between 37-42°C. 
Increasing incubation temperature as well as duration leads to improved outcome for 
the long TALEN mRNA (data not shown).  
After incubation, 1 #l RNase-free DNase is added to the reaction and incubated for 
further 15 minutes at 37°C. Subsequently, the RNA is cleaned up using the 
Nucleospin RNA II kit as described above.  
For generation of synthetic mRNA as published by Warren (Warren et al., 2010) the 
modified ribonucleotides methyl-CTP and pseudo-UTP were used. These 
modifications are supposed to reduce innate immunogenic reactions caused by 
ssRNA (Warren et al., 2010). In order to investigate these effects, next to the 
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modified version, a modified as well as an unmodified version of GFP-mRNA was 
synthesized using the standard ribonucleotides CTP and UTP.  
Capping of synthetic mRNA 
Following the IVT reaction, the obtained synthetic mRNA needs to be capped, as the 
5´Cap also decreases the reactions of the innate immune system and leads to 
increased stability. For this purpose, two kits are used for simultaneous capping: 
ScriptCap™ m7G Capping System and ScriptCap™ 2´-O.Methyltransferase Kit 
(Cellscript).   
For that, 60 #g IVT product is adjusted with H2O to a volume of 67 #l. This RNA 
solution gets heat-denatured for 10 minutes at 65°C and subsequently cooled on ice.  
 
Reaction mix: 
10 #l 10x ScriptCap Capping Buffer 
10 #l 10mM GTP 
2.5 #l 20mM SAM 
2.5 #l 20mM ScriptGuard RNase Inhibitor 
4 #l ScriptCap 2´-O-Methyltransferase (100 U/#l) 
4 #l ScriptCap Capping Emzyme (10 U/#l) 
67 #l Heat-denatured RNA 
The capping mix was incubated for 30 minutes at 37°C. 
 
Afterwards the mRNA is cleaned up using the Nucleospin RNA II kit (Macherey-
Nagel) resulting in a RNA solution with a concentration between 500 and 1500 ng/#l. 
The RNA can be washed of the column with sterile nuclease-free water; this 
procedure was appropriate to use the synthetic mRNA for cell culture applications.  
 
2.3.5 Agarose gel electrophoresis 
In order to estimate the size and quality of RNA molecules, agarose gel 
electrophoresis is used. Two different kinds of gel electrophoresis can be performed.  
 
Native gel electrophoresis 
The advantage of the native gel electrophoresis for RNA is that a good visualization 
is possible and that it can be performed at the normal ethidium bromide working 
bench without any further precautions. The disadvantage is that RNA is easily 
degraded in native conditions. 
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The gel gets prepared as described above for DNA electrophoresis (2.2.6). TAE 
Buffer is prepared freshly to avoid RNase contaminations.  
As soon as the gel is solidified, probes are loaded to the slots. Prior to loading, the 
samples (1#g of RNA each) and 2 #g of the ssRNA ladder (NEB) are prepared using 
2x RNA loading buffer (supplied with the ladder) and boiled for 10 minutes at 70°C, 
subsequently chilled on ice.  
Electrophoresis is performed in TAE Buffer. A voltage of 5 V/cm of gel is applied for 
30 minutes to one hour. RNA fragments can be visualized using a UV 
transilluminator. 
 
Denaturing gel electrophoresis 
To prevent degradation during electrophoresis, denaturing gel electrophoresis can be 
performed. A disadvantage of this method is that the visibility of the bands is not as 
good as in the native gel electrophoresis. Furthermore, the use of strong denaturing 
substances as formaldehyde requires special security precautions. Contact with skin 
and inhalation of the vapors need to be avoided.  
For preparation, agarose (1% w/v) is boiled in water and the respective amounts of 
10x MOPS Buffer and formaldehyde (final concentration 7% v/v) are added 
afterwards. Samples and ladder are prepared as described above, unless before 
loading ethidium bromide is added at a final concentration of 10 #g/ml to them. 
Electrophoresis is performed in 1x MOPS buffer with an applied voltage of 5 V/cm for 
30 minutes to one hour. Visualization is performed as described before.  
 
10x MOPS Buffer: 400mM MOPS, pH 7.0 
 0.1M sodium acetate 
 0.01M EDTA 
 
2.4 Proteins 
2.4.1 Isolation of total protein 
To analyze total protein of cell lysates, cells are lysed using RIPA Buffer. Prior to use, 
the RIPA Buffer is prepared freshly. For that, 200 #l of each 5x stock solution are 
mixed resulting in the wanted 1x concentration of each component; 10 #l of HALT 
protease inhibitor are added to prevent degradation of the proteins.  
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Cells are lysed directly on the cell culture dishes. For that, medium gets aspirated 
and the cells are washed once with PBS. Subsequently, the dishes are put on ice, 
cold RIPA Buffer is added (60 #l per well of 6well dish). Following 20 minutes of 
incubation, cells get detached using a cell scraper. The lysate is transferred to a 
reaction tube and centrifuged for 20 minutes at a speed of 16 000 rpm at 4°C. The 
supernatant is collected in a new reaction tube and stored at -20°C. 
 
RIPA Buffer Stock Solutions: 
5x Buffer 250mM Tris-HCl, pH 7.5 
5mM EDTA 
5x NaCl 750mM NaCl 
5x DOC Deoxycholic acid, sodium salt 
5x SDS 0.5% Lauryl sulfate 
5x Igepal 5% Igepal 
 
2.4.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Polyacrylamide gel 
Proteins are separated using a discontinuous polyacrylamide gel consisting of a 
stacking gel and a separation gel (Laemmli, 1970). Due to a lower concentration of 
acrylamide, the pores in the stacking gel are bigger; therefore all the proteins 
accumulate in the stacking gel and enter the separation gel simultaneously. The 
higher amount of acrylamide in the separation gel leads to a smaller pore size 
leading to a separation of the proteins according to their molecular masses.  
At preparation, first the separation gel is poured into a tightly assembled gel chamber 
and subsequently covered with isopropanol to ensure a plane surface. After 
polymerization, isopropanol gets removed using Whatman Paper and the stacking 
gel is poured into the gel chamber. A comb is inserted to the stacking gel. 
Polymerization is accomplished after approximately 30 minutes. 
 
Stacking gel: 3.05 ml H2O 
 0.65 ml 30% Bis-/Acrylamide 
 25 #l 10% APS 
 5 #l TEMED 
 1.25 ml TrisCl/SDS pH 6.8 
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Separation gel: 3.15 ml H2O 
 2.5 ml 30% Bis-/Acrylamide 
 30 #l 10% APS 
 8 #l TEMED 
 1.9 ml Tris-Cl/SDS pH 8.8 
 
Sample preparation for SDS-PAGE 
Before loading the protein sample onto the polyacrylamide gel, it has to be diluted in 
2x sodium dodecyl sulfate (SDS) buffer. SDS is a highly anionic detergent and has 
two beneficial effects for protein separation; first it charges the proteins negatively 
according to their size, and second it denatures the secondary and tertiary structures 
of the proteins. !-mercaptoethanol, another component of the 2x SDS buffer, 
reduces the disulfide bonds. 
For preparation, the protein lysate is diluted 1:1 with 2x SDS buffer. After heating it to 
95°C for 5 minutes, the samples are cooled down on ice and centrifuged 
subsequently. 
 
2x SDS Buffer: 250mM Tris-Cl, pH 6,8 
 6% (w/v) SDS 
 20% (w/v) glycerol 
 0.01% (w/v) bromphenol blue 
 6% (w/v) !-mercaptoethanol 
  
Gel electrophoresis 
After preparation, the samples are either frozen down for later use or directly loaded 
onto the gel. 5 to 10 #l are loaded in each slot. Additionally, the Prestained Protein 
Marker is loaded in at least one slot to determine the size of the proteins. 
After loading, the gel gets covered with SDS Running Buffer. Electrophoresis is 
carried out at 200V. The duration depends on the expected size of the proteins to be 
separated. After the gel run, the gel can be stained or used for an immunoblot. 
 
SDS Running Buffer: 25mM Tris 
 192mM Glycin 
 0.1% SDS, pH 8.3 
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Staining of gels 
After completion of the gel run, the gel is transferred into a glass dish, washed with 
ddH2O and then covered with Imperial Protein Stain Solution (Perbio). After an 
incubation of at least 1 hour the staining solution gets removed, ddH2O and a tissue 
are added. On the next day, the residual staining was washed of the gel; only the 
proteins in the gel lanes remain stained. Gels are dried using the DryEase® System 
(Life Technologies). Shortly, two membranes supplied with the system and the gel 
are incubated with Gel Drying Buffer for 2 minutes and then fixed into a frame. After 
24 hours, the gel is dried and can be scanned for documentation. 
 
Gel Drying Buffer: 20% methanol 
 2% glycerol 
  
 
 
2.4.3 Immunoblot 
To determine whether a protein is present in the whole protein lysates of cells and to 
estimate the running size of this protein, an immunoblot can be used. Briefly, the 
proteins separated using SDS-PAGE first need to be blotted onto a membrane. After 
that, an antibody against the protein to be detected gets incubated with the 
membrane. A secondary antibody coupled to an enzyme enables detection. 
 
Blotting 
The proteins are blotted onto the membrane using the so-called “wet” technique, 
meaning the whole blotting complex is covered with Blot Transfer Buffer all the time. 
First, the gel, a piece of blotting membrane in the size of the gel, and 6 Whatman 
papers in the same size as well as two fiber pads get pre-wetted in Blot Transfer 
Buffer. To assemble the blot, one fiber pad and 3 Whatman Paper are put onto the 
black side of the cassette followed by the gel and the membrane. On top, another 3 
Whatman papers and the second fiber pad complete the assembly. The cassette is 
closed and put into a Mini Trans-Blot buffer tank together with a cooling unit and 
covered with Blot Transfer Buffer. An electric current of 100V is applied for 1 hour.  
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Blot Transfer Buffer (wet): 25mM Tris 
 192mM Glycin 
 20% methanol 
  
 
Blocking and antibody incubation 
After the blotting, the membrane is put into a 50 ml centrifugation tube. Depending on 
the antibody to be used, the blocking solution differs; Stat-3 and pStat-3 are detected 
using blocking solution and antibody solution containing BSA. After one hour of 
incubation at room temperature in 5 ml of the appropriate blocking solution, the first 
antibody is diluted in 3 ml of 2.5% BSA/TBS-T or 2.5% milk powder/TBS-T 
respectively. Incubation is either performed overnight at 4°C or for one hour at room 
temperature. Subsequently, the membrane gets washed 3 times for each 5 minutes 
with TBS-T, followed by the incubation of the secondary antibody, which is HRP-
coupled and diluted 1:1000, as described before overnight at 4°C or 1 hour at room 
temperature. After three times of washing with TBS-T the membrane is ready for 
detection. All incubation and washing steps are performed in the centrifugation tube 
while rotating it overhead to prevent drying out of the membrane and to ensure a full 
coverage of the membrane.  
 
Blocking solution 1: 5% milk powder 
 TBS-T 
 
Blocking solution 2: 5% bovine serum albumine (BSA) 
 TBS-T 
 
TBS-T: 50mM Tris-HCl, pH 7.4 
 150mM NaCl 
 0.05% Tween 20 (v/v) 
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Detection 
After antibody incubations, the immunoblot is ready to be detected using either the 
SuperSignal West Pico Substrate or the SuperSignal West Femto Substrate (Thermo 
Scientific). The detection itself is carried out using the ChemiDoc XRS system 
(Biorad), which harbors a CCD camera able to detect the emerging 
chemiluminescence.  
 
Immunoblot stripping 
In some cases it is interesting to check whether a second protein can also be 
detected on the membrane. For that, the antibodies used before can be stripped of 
the membrane. To accomplish this, the membrane is incubated at 50°C in Stripping 
Buffer containing strong detergents. After 30 minutes of incubation, the blot gets 
washed with PBS (Life Technologies) 2 times for 30 minutes and another 5 times for 
10 minutes. After that, the blot is ready to be used again, starting with blocking. 
 
Stripping Buffer: 2% SDS 
 100mM !-mercaptoethanol 
 50mM Tris-Cl, pH 6.8 
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2.5 Cell Culture 
All cells are cultivated at 37°C in a humidified atmosphere with 5% CO2. 
All cell culture procedures are performed under a sterile working bench with laminar 
flow using sterile media, glass and plastic ware. 
 
2.5.1 Coating of cell culture dishes 
For cell culture, only cell culture treated plastic ware was used. Nevertheless, for 
some cells, these dishes had to be coated to assure appropriate culture conditions.  
 
Matrigel™ coating 
hPSCs used in this thesis are cultivated on 6well-dishes coated with BD Matrigel™ 
hESC-qualified matrix (BD Biosciences). Matrigel™ is aliquoted and frozen following 
manufacturer’s instructions; the volume of the aliquots is batch-dependent. For use, 
one aliquot of Matrigel™ gets thawed on ice, once thawed it is immediately 
transferred into a centrifugation tube containing 25 ml of ice-cold DMEM/F-12. Into 
each well of a 6well-dish, 1 ml of the Matrigel™-dilution is pipetted. The dishes are 
sealed with Parafilm and stored at 4°C for up to 2 weeks. Before use, the dishes are 
put to room temperature for 30 minutes. Before plating cells on the dishes, the 
Matrigel™-dilution has to be aspirated, no washing is necessary.  
 
PO/Ln coating 
The cultivation of lt-NES cells requires dishes coated with Polyornithine (PO) and 
Laminin (Ln). First, 1 ml of PO (1.5 mg/ml in PBS) is pipetted into each well of a 
6well-dish and incubated for at least 2 hours at 37°C. After PO incubation, the dishes 
are washed twice with PBS and subsequently Laminin is added at a concentration of 
1 #g/ml in PBS. After 2 hours of incubation at 37°C, the dishes are used immediately 
or sealed with Parafilm and stored for up to one week at 4°C.  
 
Gelatin coating 
When needed for experiments as mRNA transfection, human fibroblasts and 293T 
cells are seeded on gelatin-coated dishes. For that, cell culture plastic ware is 
incubated with 0.1% (v/v) Gelatin in H2O for 20 minutes at 37°C. 
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2.5.2 Cultivation of human pluripotent stem cells (hPSCs) 
hPSCs routinely are cultivated in 6well-dishes coated with BD Matrigel™ hESC-
qualified matrix (BD Biosciences) in mTeSR™1 medium (STEMCELL Technologies). 
Cell culture medium is changed daily and the cells are passaged at a confluence of 
around 70-80%. For passaging, culture medium gets aspirated and replaced by 1 ml 
of fresh mTeSR™1, then the colonies are scraped of using a cell scraper. The cell 
suspension is gently pipetted up and down three times with a 1000 #l-tip to dissociate 
the colonies into smaller clumps. The cells are transferred into a 15 ml centrifuge 
tube; the volume gets adjusted to obtain the desired dilution. An appropriate amount 
of cell solution is then transferred on a new Matrigel™-coated 6well dish, e.g. for a 
splitting ratio of 1:6, one well of cells are detached, the volume is adjusted to 3 ml, 
and 500 #l of the solution is transferred to each well of the new dish already 
containing 1 ml of mTeSR™1, resulting in a total volume of 1.5 ml/well of culture 
medium.  
In order to test the influence of the IL-6/sIL-6R fusion protein, mTeSR™1 is replaced 
with hPSC Medium containing the fusion protein. hPSCs require a layer of radiated 
mouse fibroblasts, so-called Feeder Cells, when not cultivated in special systems as 
the mTeSR™1 system. It gets tested whether the fusion protein can compensate for 
the lack of Feeder Cells. 
 
hPSC Medium: Knockout DMEM 
 20% Serum Replacement 
 1:100 NEAA 
 1:100 GlutaMax 
 1:500 !-Mercaptoethanol 
 10 ng/ml bFGF 
 200 pg/ml IL-6/sIL-6R  
 
As a control, hPSC Medium is supplemented with human LIF at a concentration of  
10 ng/ml instead of fusion protein.  
 
2.5.2.1 Single cell suspension of hPSCs 
For some experiments it is necessary to plate hPSCs as single cells instead of 
colonies. For that, one hour before splitting, the cells are incubated with 10#M Rock-
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inhibitor at 37°C, 5% CO2. After 1 hour, the culture medium is aspirated and the cells 
are washed once with PBS. PBS is replaced with 500 #l of 0.5mM EDTA in PBS. 
After an incubation of 10-20 minutes at 37°C, 5% CO2, cells are detached. Adding 
500 #l of culture medium stops the enzymatic reaction. The cells are dissociated by 
roughly pipetting the cells up and down using a 1000 #l-pipette. The cell solution is 
transferred into a 15 ml centrifuge tube and the well is washed once with 2 ml of 
culture medium which then also gets transferred into the tube. The single cells are 
centrifuged at 1000 rpm for 5 minutes. Following, the supernatant is aspirated, and 
the cell pellet is resuspended in an appropriate volume. The single cell suspension 
were transferred onto a new Matrigel™-coated 6well dish in mTeSR™1 
supplemented with 10#M of Rock-inhibitor.  
 
2.5.2.2 Freezing and thawing of hPSCs 
To freeze hPSCs, a single cell suspension is done following the protocol described in 
2.5.2.1. After centrifugation, the supernatant is aspirated. The cell pellet gets 
resuspended in an appropriate volume of hPSC Freezing Medium (1 ml freezing 
medium per well of a 6well plate). The cell suspension immediately is pipetted into 
cryovials that then are put into a Mr. Frosty™ freezing container (Nalgene) filled with 
isopropanol. After 1 day at -80°C, cells ideally are transferred in a liquid nitrogen 
container at -196°C for longer storage. 
 
To thaw hPSCs, a cryovial with cell suspension is thawed in a 37°C water bath. As 
soon as only a small clump of medium was left frozen, the content of the vial is 
transferred in a 15 ml centrifugation tube already containing 9 ml of hPSC medium.  
After a centrifugation at 1000 rpm for 4 minutes, supernatant is aspirated and the cell 
pellet are resuspended in hPSC medium. The cells of a confluent well of a 6well 
plate, corresponding to about 2 x 106 cells, are usually seeded onto 3 wells of a 
Matrigel™-coated 6well plate. It is essential to supplement the hPSC medium with 
10#M ROCK inhibitor for at least 24 hours.  
 
hPSC Freezing Medium: 10% DMSO 
 90% Serum Replacement 
 
  
Materials and Methods 
 
! 48 
2.5.3 Cultivation of human lt-NES cells 
lt-NES cells routinely are cultivated in 6well-dishes coated with PO/Ln in lt-NES cell 
medium. Medium is changed every day and cells are splitted when reaching 100% 
confluence. For passaging, the cell culture medium is aspirated and the cells are 
washed once with PBS (Life Technologies). 1 ml of trypsin is added per well and the 
cells are incubated for 5 to 10 minutes at 37°C, the detachment of the cells is 
observed with the microscope. As soon as the cells are detached, 1 ml/well of trypsin 
inhibitor is added to stop the enzymatic reaction. The cell suspension is transferred 
into a 15 ml centrifuge tube; the well is washed once with 2 ml of lt-NES cell medium. 
After 4 minutes of centrifugation at 1000rpm/4°C, the supernatant gets aspirated and 
the pellet is resuspended in an appropriate volume of lt-NES cell medium. The 
splitting ratio is between 1:3 and 1:6.  
 
lt-NES cell medium: DMEM/F-12 
 1% N2 
 0.1% B27 
 1:100 Glucose Stock Solution 
 1:1000 bFGF 
 1:1000 EGF 
 0.8#M CHIR 
 
 
2.5.4 Cultivation of human fibroblasts, HEK 293T cells and HepG2 cells 
Human fibroblasts, HEK 293T cells and HepG2 cells are cultivated in Fibroblast 
Medium on uncoated cell culture dishes. Cells are splitted after reaching 90-95% 
confluence. For that, the cell culture medium is removed and the cells are washed 
once with PBS. An appropriate volume of trypsin is added to the cells and incubated 
for 3-5 minutes at 37°C. After detachment, addition of an equal volume of fibroblast 
medium stops the enzymatic reaction. The serum in the medium is sufficient to inhibit 
trypsin; no addition of trypsin inhibitor is needed. The cell suspension is transferred 
into a 15 ml centrifuge tube; the dish is washed once with fibroblast medium that is 
also transferred to the tube. After 4 minutes centrifugation at 1200rpm, the 
supernatant is discarded and the cell pellet is resuspended in an appropriate volume. 
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The splitting ratio lies between 1:4 and 1:10 for human fibroblasts and HepG2 cells 
and between 1:10 and 1:30 for HEK 293T cells. 
 
Fibroblast Medium: DMEM (high glucose) 
 10% FCS 
 1:100 NEAA 
 1:100 Sodium Pyruvate 
 1:100 GlutaMAX 
 
 
2.5.5 Cultivation of murine pluripotent stem cells (mPSCs) 
mPSCs are cultivated on gelatin coated cell culture dishes in mPSC Medium. 
Medium is changed on a daily base. The cells are splitted every 3 to 4 days, 
depending on the confluence and the size of the colonies. To split mPSCs, cell 
culture medium gets aspirated and the cells are washed once with PBS. An 
appropriate amount of Trypsin is added to the cells following an incubation of 4 to 6 
minutes at 37°C. After incubation, the enzymatic reaction is stopped by adding the 
same amount of mPSC Medium. The cell suspension is pipetted up and down to 
dissociate the colonies and subsequently transferred into a 15 ml centrifuge tube for 
a centrifugation at 1000rpm for 4 minutes. The supernatant is aspirated and the cells 
get resuspended in fresh mPSC medium. The splitting ratio is between 1:20 and 
1:50.  
For a dose response test, the mPSC Medium gets modified, instead of LIF different 
concentrations of the IL-6/sIL-6R fusion protein are added.  
 
mPSC Medium: DMEM (high glucose) 
 15% FCS 
 1:100 NEAA 
 1:100 Sodium Pyruvate 
 1:500 !-Mercaptoethanol 
 1:10 000 LIF (10ng/ml)  
or IL-6/sIL-6R in different concentrations 
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2.5.6 Counting of cells 
For some experiments it is necessary to determine the exact cell number, e.g. to 
plate cells for mRNA transfection. For that, cells are detached as described before. 
20 #l of the cell suspension are transferred into a reaction tube containing 20 #l of 
trypan blue. After mixing, 20 #l of the cell suspension are pipetted in a Neubauer 
counting chamber. The mean cell number per main squares is determined by 
counting four main squares.  
In case of dense cell suspensions, a dilution with PBS can be useful. 
With the following formula, the cell number can be calculated: 
 
cells/ml = (mean cell number/main square) x dilution factor x 104 
 
 
2.5.7 mRNA transfection 
Cells are plated 24 hours before transfection as single cells on the required coating. 
The cell number is determined as described before. Due to toxicity, the different cell 
lines can not all be transfected with the same transfection reagent, so 
Lipofectamine® LTX (Life Technologies) and TransIT® mRNA transfection reagent 
(MirusBio) have to be used. In table 2.13 the cell number plated per well of a 6well 
plate and the transfection reagent is shown. 
 
Table 2.13: plated cell number for mRNA transfection 
Cells Number/well 
Transfection 
reagent 
hPSCs 1 000 000 Lipofectamine® LTX 
lt-NES 200 000 Lipofectamine® LTX 
hFibroblasts 150 000 TransIT® 
HEK 293T 300 000 TransIT® 
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2.5.7.1 Transfection with Lipofectamine® LTX 
Per well to be transfected, an appropriate amount of mRNA (usually between 500 ng 
and 1 #g) is diluted in 100 #l OptiMEM in a reaction tube. 1.5 #l of PlusReagent were 
added. After an incubation of 5 minutes at room temperature, 4.5 #l Lipofectamine® 
LTX are added, the solution is incubated for 20 minutes at room temperature. During 
the last incubation, the medium on the cells is replaced with a 1:1 mixture of the 
normal cell culture medium and OptiMEM. This is necessary because some 
components of the medium as serum replacement can interfere with the lipoparticles. 
After incubation, the transfection mix is added dropwisely to the cells.  
 
2.5.7.2 Transfection with TransIT® 
Per well to be transfected, an appropriate amount of mRNA (usually between 500 ng 
and 1 #g) is diluted in 100 #l OptiMEM in a reaction tube. Subsequently, Boost 
reagent is added at an amount of 1 #l per 1 #g RNA. After mixing, TransIT® reagent 
is added (1 #l per 1 #g RNA). The solution is mixed again and incubated at room 
temperature. During incubation, the medium on the cells is exchanged as described 
before in the protocol for transfection with Lipofectamine®LTX. After 2 to 5 minutes of 
incubation, the solution is added dropwisely to the cells. 
After addition of the transfection mixture the cells subsequently are put in a 37°C 
incubator and incubated over night. 16 hours after mRNA transfection, the medium is 
exchanged with fresh medium. 
 
2.5.7.3 Treatment with B18R 
To examine whether the TLR3 activity affects mRNA transfection efficiencies, the 
TLR3 inhibitor B18R is added in some experiments. For that, B18R is added at a 
concentration of 200 ng/ml to the cells one hour prior mRNA transfection. Before that, 
the medium on the cells is replaced with a 1:1 mixture of the normal cell culture 
medium and OptiMEM. The transfection protocol is followed as described above, 
except the medium change during incubation.   
2.6 Flow Cytometry 
Flow cytometry is a method to quantify fluorescent events. For example it is possible 
to stain cells for surface markers and use a secondary antibody that is coupled to a 
fluorescent dye. In this thesis, flow cytometry was used to quantify efficiencies of 
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GFP-mRNA transfection. For analysis, the transfected cells are detached as 
described above (see 2.5). In case of hPSCs, the cells need to be singularized. After 
centrifugation, the pellets are resuspended in a small volume of cold PBS (200 – 500  
#l). Subsequently, the cell solutions are transferred into flow cytometry tubes, put on 
ice and immediately measured. 
Data acquisition is performed using CellQuest Acquisition software; obtained data 
can be analyzed using FlowJo software. 
2.7 Enzyme-linked immunosorbent assay (ELISA) 
An enzyme-linked immunosorbent assay (ELISA) is an assay that enables to quantify 
the amount of a substance in a sample, using antibodies against this antigen. In this 
thesis, the amount of phosphorylated Stat3 (pStat3) is determined with the 
PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA Kit from CellSignaling 
Technology. 
The assay is performed according to manufacturers protocol.  
Results 
 
!53 
3 Results 
3.1 The role of Stat3 in hPSC 
The role of Stat3 signaling in human pluripotent stem cells is discussed 
controversially. 
In murine PSCs, Stat3 signaling needs to be activated via LIF addition to maintain 
pluripotency. So far, the widespread opinion is that hPSCs are in the primed state of 
pluripotency and do not respond to extrinsic factors with Stat3 signaling. Only the 
naïve counterparts react with Stat3 signaling upon stimulation and are even 
dependent on Stat3 activation (Gafni et al., 2013).  
In 2010, it was published that hPSCs could be maintained pluripotent in suspension 
cultures by adding the chimeric fusion protein IL-6/sIL-6R, which is a LIF agonist and 
was claimed to be more potent than LIF (Amit et al., 2010). If the reason for the 
absence of Stat3 signaling in hPSCs is the missing of LIF receptors on its cell 
surface, the fusion protein could circumvent this lack; only the gp130 receptor needs 
to be presented on the cell surface to initiate Stat3 signaling. 
In suspension cultures, cells do not have a matrix to bind to, they can only attach to 
themselves. The standard spontaneous differentiation protocol for hPSCs requires as 
a first step to detach the colonies and bring them into suspension. The medium used 
for that is hPSC medium without supplementation of bFGF. In the published protocol, 
Amit and colleagues use the same medium, only supplemented with bFGF and a IL-
6/sIL-6R fusion protein, for maintenance in suspension (Amit et al., 2011). They did 
not observe a lot of spontaneous differentiation. This let suggest that the IL-6/sIL-6R 
fusion protein could also enable hPSCs to be maintained pluripotent without a feeder 
layer. Cultivation of hPSCs without a feeder cell layer of irradiated mouse embryonic 
fibroblasts normally requires special coatings and cell culture mediums, as the 
mTeSR™-1/Matrigel™ system. To evaluate this, the company Merck kindly provided 
the IL-6/sIL-6R fusion protein in order to repeat the suspension culture experiments 
(performed in another group) and to transfer the results to adherent conditions.  
As a first step, the IL-6/sIL-6R fusion protein was examined on quality aspects. An 
SDS gel stained with Imperial Protein Stain Solution showed that the delivered 
protein was pure, only a single band could be detected (Figure 3.1). The marker 
revealed that the size of the protein in the solution was slightly less than 80kDa, 
Results 
 
! 54 
which is consistent with the size of the IL-6/sIL-6R fusion protein given by the 
manufacturer. 
 
Figure 3.1: SDS-PAGE analysis to estimate size and purity of the IL-6/sIL-6R fusion 
protein 
SDS-PAGE reveals a single protein with a size of around 80kDa; no contamination could be 
seen in the lanes. 1 #g or 5 #g of the fusion protein were loaded in two slots of the SDS gel; 
PM= proteinmarker 
 
Furthermore, the concentration of the IL-6/sIL-6R fusion protein was estimated using 
a Bradford assay. The concentration given by the manufacturer was 680 #g/ml. The 
measured concentration differed from this; the Bradford assay resulted in a 
concentration of 318 #g/ml. All further dilutions of the IL-6/sIL-6R fusion protein were 
calculated using the measured concentration.  
 
3.1.1 hPSCs express Stat3 
After confirming the quality of the IL-6/sIL-6R fusion protein, it was checked whether 
hPSCs that served as cellular models in this thesis in fact express Stat3. If Stat3 is 
not expressed in hPSCs, no activation of the Stat3 signaling is expected to occur. 
Whole cell protein lysates of I3 hPSCs were loaded on a gel and an SDS-PAGE was 
performed. The cells were either cultivated in full hPSC medium without additional 
supplements (Figure 3.2, lane 1) or in presence of the IL-6/sIL-6R fusion protein 
(lane 2) or human LIF (lane 3) for 1 day, respectively.  The IL-6/sIL-6R fusion protein 
was supplied at a concentration of 200 pg/ml, which was in the range of the 
published concentration feasible to maintain pluripotency in suspension cultures (100 
pg/ml; Amit et al., 2010). hLIF was added with a final concentration of 10 ng/ml. 
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Figure 3.2: Immunoblot confirms Stat3 expression in hPSCs 
This immunoblot exemplarily shows a strong Stat3 signal for I3 hESCs cultivated in hPSC 
medium only and supplemented with IL-6/sIL-6R fusion protein and hLIF, respectively. The 
signal for cells treated with LIF appears to be weaker. 1= control (hPSC medium), 2= cells 
treated with IL-6/sIL-6R fusion protein, 3= cells treated with hLIF 
Development: Stat3, actin= SuperSignal West Pico Substrate 
 
The immunoblot depicted in figure 3.2 shows that hPSCs express Stat3. It appeared 
that, when compared to the actin control, cells treated with the IL-6/sIL-6R fusion 
protein express more Stat3. This could not be observed in this impact in iLB-30-r12 
hiPSCs.   
 
3.1.2 Stat3 cannot be activated in hPSCs by IL-6/sIL-6R fusion protein 
Next, experiments to check whether the IL-6/sIL-6R fusion protein can activate Stat3 
signaling in hPSCs were performed. Medium conditions were changed on iLB-30-r12 
hiPSCs that were plated on Matrigel™ hESC qualified matrix. Instead of mTeSR™-1, 
hPSC medium supplemented with either 200 pg/ml IL-6/sIL-6R fusion protein or 10 
ng/ml hLIF was added to the cells plated as small clumps one day in advance. One 
day after the medium change (figure 3.3, A-D), IL-6/sIL-6R fusion protein as well as 
hLIF changes the hPSC morphology. In the absence of these factors, cells 
spontaneously lost the compactness of the colonies indicating differentiation (Figure 
3.3, B). The colonies lost its sharp borders, and in the inside of the colonies single 
cells could be distinguished, which is normally a first sign of differentiation. In 
contrast to that, the presence of both, IL-6/sIL-6R fusion protein (Figure 3.3, C) and 
hLIF (Figure 3.3, D), kept the colonies in a compact shape, comparable to the 
morphology of the positive control, cells cultured in mTeSR™-1 (Figure 3.3, A). 
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Figure 3.3: Morphological changes after one and 2 days of application show disability 
of the IL-6/sIL-6R fusion protein to maintain pluripotency-associated morphology 
hPSCs (iLB-30-r12) were treated with IL-6/sIL-6R fusion protein or hLIF as indicated.  
(A-D): Examination of the morphology 24 hours after changing the medium conditions 
indicate that spontaneous differentiation can be circumvented by the presence of the fusion 
protein (C) or hLIF (D) in hPSC medium. The positive control in mTeSR medium (A) exhibits 
an undifferentiated morphology, whereas cells in the negative control in hPSC medium 
without fusion protein or hLIF starts to differentiate.  
(E-H): 48 hours after the change of the medium conditions, also the cells treated with the 
fusion protein (G) and hLIF (H) begin to differentiate and exhibit the same morphology as the 
negative control with hPSC medium only(F). The positive control in mTeSR medium retains 
its morphology (E).  
Magnification 40x 
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Two days after the change of the medium conditions, this effect could not be 
observed anymore. While the cells under control conditions still exhibited the 
morphology of undifferentiated hPSC (Figure 3.3, E), the cells treated either with IL-
6/sIL-6R fusion protein (Figure 3.3, G) or hLIF (Figure 3.3, H) showed a changed 
morphology. The colonies lost their compactness. Therefore, after two days they 
resembled the negative control (hPSC medium without supplements; Figure 3.3, F) 
and not the positive mTeSR™-1 control (Figure 3.3, E). This indicates that the 
spontaneous differentiation was just delayed by the addition of LIF or fusion protein.  
Notably, there was no apparent difference between the cells treated with LIF or 
fusion protein. This suggests that the reported failure of activation of Stat3 signaling 
is not necessarily due to lacking LIF receptors, as hLIF has an effect on the culture. 
The morphological changes showed in Figure 3.3 do only give a hint that hPSCs 
differentiate in the presence of IL-6/sIL-6R fusion protein or LIF. Further analysis of 
the differentiation state of the treated cells could not be performed, because an 
elongated culture under these conditions led to the loss of the cells. It is a commonly 
known feature of Matrigel™ matrix that spontaneously differentiated cells detach 
from the matrix and consequently get lost.  
The reported change in morphology did not give any indication whether the IL-6/sIL-
6R fusion protein and LIF did fail in activating Stat3 signaling. Possibly Stat3 was 
phosphorylated, but this was not sufficient to maintain pluripotency in adherent 
cultures. Therefore, the phosphorylation of Stat3 should be investigated by 
performing an immunoblot with an antibody against the phosphorylated and thus 
activated form of Stat3 (pStat3). Whole cell protein lysates were obtained from I3 
hESCs cultivated for 24 hours either in hPSC medium without supplement (Figure 
3.4, lane 1) or IL-6/sIL-6R fusion protein (200 pg/ml; Figure 3.4, lane 2) or hLIF (10 
ng/ml; Figure 3.4, lane 3). 
No phosphorylated Stat3 could be detected in protein lysates from control cells. 
Surprisingly, Stat3 was found phosphorylated in hPSCs, but not by IL-6/sIL-6R fusion 
protein but by hLIF. Nevertheless, the signal of pStat3 was very weak, indicating that 
Stat3 activation is a rare event in hPSCs. For detection, the membrane had to be 
incubated for several seconds with the SuperSignal West Femto Substrate, which is 
only necessary for low protein concentrations. These findings were made in 4 
individual experiments. 
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Figure 3.4: IL-6/sIL-6R fusion protein fails to phosphorylate Stat3 in hPSCs 
I3 hESCs were cultivated for 24 hours in the presence of 200 pg/ml IL-6/sIL-6R fusion protein 
(lane 2) or 10 ng/ml hLIF (lane 3). As a control, cells were cultured in hPSC medium without 
addition of an activator of Stat3 signaling (lane 1). In this exemplary immunoblot, no 
phosphorylated Stat3 can be seen for the fusion protein (lane 2).  
Development: pStat3= SuperSignal West Femto Substrate; actin= SuperSignal West Pico 
Substrate 
 
Further validation of Stat3 signaling upon treatment with the IL-6/sIL-6R fusion 
protein was performed by investigating the expression of Stat3 target genes using 
quantitative RT-PCR (qRT-PCR).  
For that, I3 hESCs were cultivated in hPSC medium with different concentrations of 
IL-6/sIL-6R fusion protein. As a control, hPSC medium without supplementation of 
Stat3-stimulators was added to the cells. As another control, RNA was prepared from 
cells that were cultivated under standard conditions, meaning in mTeSR™-1 
medium. Before starting the treatment of the cells, cells were starved meaning 
cultivated in hPSC medium without supplements for 16 hours. Following this, cells 
were kept in the corresponding media for 6 hours, then RNA was isolated and 
reverse transcribed. qRT-PCR was performed for two candidate target genes Pim1 
and Socs3, which are known to be expressed after activation of Stat3 signaling. The 
results were normalized against the housekeeping gene GAPDH. In Figure 3.5, the 
expression rates relative to the expression in mTeSR™-1 cultivated cells (“mTeSR”) 
can be seen.  
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Figure 3.5: Increasing concentrations of IL-6/sIL-6R fusion protein cannot activate the 
expression of Stat3 target genes  
I3 hESCs were treated for 6 hours with different concentrations of IL-6/s-IL6R fusion protein; 
RNA was isolated subsequently. As a control, hESCs were cultured in hPSC medium lacking 
any Stat3 stimulator (“ctrl”). qRT-PCR was performed to check for expression of the two 
Stat3 target genes Pim1 (dark grey bars) and Socs3 (light grey bars). Bars show expression 
relative to cells cultured under standard conditions (“mTeSR”). 
Results were normalized against GAPDH. All RT-PCRs were performed in triplicates; error 
bars show standard deviation. 
 
Pim1 expression (Figure 3.5, dark grey bars) decreased when medium was switched 
from mTeSR™-1 to hPSC medium without supplements (“ctrl”), which could indicate 
that mTeSR™-1 contains substances inducing Pim1 expression, whereas the hPSC 
medium lacks a stimulator. Contradictory, the addition of different concentrations of 
the IL-6/sIL-6R fusion protein did not lead to an increase of Pim1 expression. No 
dose dependent effect could be observed. This indicates that the IL-6/sIL-6R fusion 
protein is not feasible to activate Pim1 expression at all and that not only the 
concentrations needed to be adjusted.  
No positive effect of IL-6/sIL-6R fusion protein could also be observed for another 
Stat3 target gene, namely Socs3 (Figure 3.5, light grey bars). The highest relative 
expression could be detected for mTeSR™-1 cultivated hPSCs. The expression of 
Socs3 even decreased with increasing IL-6/sIL-6R fusion protein concentrations.  
Notably, the concentration of the IL-6/sIL-6R fusion protein used in the published 
suspension culture protocol (Amit et al., 2010) was 100 pg/ml and therefore as low as 
the lowest concentration used in the presented experiments. Even with the double 
amount of fusion protein (200 pg/ml) no Stat3 phosphorylation could be observed on 
protein level with immunoblot (Figure 3.4). The qRT-PCR covers a higher range of 
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concentrations, but did not reveal any activation of Stat3 signaling. Even a thousand-
fold increase of the concentration did not lead to detectable increase of target gene 
expression. The only observable effect of the IL-6/sIL-6R fusion protein is the delay 
of differentiation in feeder-free cultivation of hPSCs.  
However, the fact that LIF has the same effects as the IL-6/sIL-6R fusion protein 
suggests that the fusion protein is not more potent than LIF.  
 
3.1.3 In mPSCs, Stat3 can be activated by IL-6/sIL-6R fusion protein 
In order to investigate whether the IL-6/sIL-6R fusion protein can be more potent than 
LIF, cells known to react on Stat3 activation should be tested. Murine PSCs (mPSCs) 
are known to depend on LIF presence in their cell culture medium.  
As a first test, mPSCs of the E14T line were cultured with mPSC medium either 
supplemented with 10 ng/ml LIF (ESGRO) or 200 pg/ml IL-6/sIL-6R fusion protein. 
Whole cell protein was prepared 2 days after start of treatment.  
 
 
Figure 3.6: Stat3 gets phosphorylated in mPSCs weakly upon activation with fusion 
protein 
E14T mPSCs were cultivated for 48 hours in the presence of either 200 pg/ml of IL-6/sIL-6R 
fusion protein (1) or 10 ng/ml of LIF (2). Immunoblot reveals that Stat3 is expressed in cells 
cultivated with fusion protein; only a very weak signal could be detected for pStat3 (lane 1). A 
strong signal is detectable for pStat3 in LIF dependent culture (lane 2). 
Development: pStat3= SuperSignal West Femto Substrate; Stat3, actin= SuperSignal West 
Pico Substrate 
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LIF induced a strong Stat3 phosphorylation when compared to the fusion protein, 
which only led to a weak phosphorylation of Stat3 that was hardly detected on the 
membrane. Based on this observation it was assumed that 200 pg/ml of IL-6/sIL-6R 
fusion protein may not be sufficient to activate Stat3 signaling in mPSCs. To 
investigate that, a dose-response test should be performed. 
In a dose-response test, mPSCs of the E14T line were cultivated in media containing 
different IL-6/sIL-6R fusion protein concentrations from 100 pg/ml up to 10 ng/ml. As 
a positive control, mPSCs were cultivated in their standard medium supplemented 
with 10 ng/ml ESGRO (murine LIF). As a negative control, mPSC medium without 
addition of LIF or fusion protein was used. 
After 4 days of cultivation in the different media, morphology was checked and 
pictures were taken. The positive control (Figure 3.7, A) showed a typical morphology 
with small, compact colonies that are dome-shaped. The borders of the colonies 
were sharp and refracted light. After removal of LIF, the colonies lost their compact 
form, at the outer parts of the colonies cells were growing out. The borders of the 
colonies were not bright anymore, indicating that they lost their domed shape (Figure 
3.7, B). mPSCs cultivated in the presence of 100 pg/ml IL-6/sIL-6R fusion protein 
could not be distinguished from cells without Stat3 stimulation (Figure 3.7, C). A lot of 
differentiated cells could be seen around the residuals of the colonies. The cells 
surrounding the colonies almost formed a monolayer. The same was true for cells 
cultivated with 200 pg/ml of the IL-6/sIL-6R fusion protein (Figure 3.7, D). The 
addition of 1 ng/ml of the IL-6/sIL-6R fusion protein to the mPSC medium led to a 
slight improvement: the colonies that were left appeared to have a three-dimensional 
morphology, and fewer cells were growing outside the colonies (Figure 3.7, E). Still, 
some cells grew in between indicating that 1 ng/ml of the fusion protein is not 
sufficient to replace 10ng/ml of LIF. Only the equivalent concentration of 10 ng/ml of 
the fusion protein restored the morphology of the positive control. The cells were 
growing in compact colonies, only few cells seemed to be differentiated (Figure 3.7, 
F). 
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Figure 3.7: mPSCs maintain a pluripotency-associated morphology after 4 days of 
culture with IL-6/sIL-6R fusion protein 
mPSCs tend to differentiate spontaneously when cultivated with (C) 100 pg/ml or (D) 500 
pg/ml of fusion protein.1ng/ml of fusion protein (E) leads to a tighter colony formation and 
sharper boarders, but only cells cultivated with 10 ng/ml of fusion protein (F) can mimic the 
morphology of the positive control (A) 
Magnification 40x 
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Now that it has been shown that low concentrations of the IL-6/sIL-6R fusion protein 
were not sufficient to activate Stat3, higher concentrations of the fusion protein 
should be tested. mPSCs of the E14T line were cultivated following the standard 
protocol. These cells were used as a positive control (Figure 3.8, lane 2). To exclude 
that pStat3 detection is due to residual protein phosphorylated in LIF presence, cells 
were starved overnight (16 hours) cultivating them in mPSC medium without LIF. 
After starvation, mPSC medium either with 10ng/ml LIF (Figure 3.8, lane 3) or 
different concentrations of the IL-6/sIL-6R fusion protein (Figure 3.8, lanes 4-6) was 
added. As a negative control, one batch of cells remained in mPSC medium without 
supplementation. After 30 minutes, whole cell protein lysates were prepared, an 
SDS-PAGE and an immunoblot were performed.  
 
 
 
 
Figure 3.8: Phosphorylation of Stat3 by fusion protein is weaker than by LIF 
By immunoblot it could be observed that the IL-6/sIL-6R fusion protein is able to 
phosphorylate Stat3 in mPSCs (lanes 5,6). The signal, though, is much weaker than for the 
cells that were cultivated in the presence of LIF (lanes 2, 3).  
Development: Stat3= SuperSignal West Pico Substrate; pStat3= SuperSignal West Femto 
Substrate 
 
As expected, mPSCs cultivated in the presence of LIF showed a strong signal for 
phosphorylated Stat3, either in the standard cultivation or after starvation. In Figure 
3.8 lane 1 a weak signal at the expected height for pStat3 could be observed in the 
cells growing in the absence of LIF, which likely is due to a high background. The 
addition of 1ng/ml of the IL-6/sIL-6R fusion protein to the mPSC medium did not lead 
to a notable phosphorylation of Stat3 (Figure 3.8, lane 4), but concentrations of 10 
ng/ml and 20 ng/ml showed a detectable band (Figure 3.8, lanes 5 and 6). Notably, 
there seemed to be no dose dependent effect, the pStat3 signal for 10ng/ml fusion 
protein is as strong as for 20 ng/ml. Therefore it was assumed that the IL-6/sIL-6R 
fusion protein may not be able to activate Stat3 beyond a certain extent. 
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Taken together, the results obtained by cultivating mPSCs with the IL-6/sIL-6R fusion 
protein showed that the fusion protein seems to be a functional LIF agonist, but not 
as potent as expected. In mPSCs it was possible to gain Stat3 phosphorylation and 
maintain pluripotency, unless the published concentration of 100 pg/ml was not 
sufficient. A possible reason for that might be that the fusion protein was designed to 
replace human LIF in human cells. It may be that mPSCs are not an appropriate 
model to test for IL-6/sIL-6R fusion protein activity.  
 
 
3.1.4 IL-6/sIL-6R fusion protein is not more potent than hLIF and IL-6 
To check whether the IL-6/sIL-6R fusion protein is more potent in human cells, 
HepG2 cells were taken into culture. HepG2 is a human cell line that was generated 
from a liver carcinoma and can be used as a model for polarized hepatocytes. It is 
known that Stat3 signaling can be activated in HepG2 cells (Lutticken et al., 1994). 
Therefore, they can be used to test the functionality and activity of the IL-6/sIL-6R 
fusion protein in human cells without interfering with the pluripotency status. In 
standard culture, HepG2 cells were cultured without addition of LIF. Only after plating 
cells for sample preparation for an ELISA, cells were treated for 6 hours with different 
concentrations of either hLIF, IL-6/sIL-6R fusion protein or the cytokine IL-6, which is 
not bound to its soluble receptor. LIF and IL-6 treated cells were used as a reference 
to estimate the activity of the fusion protein.  
Notably, at a concentration of 100 pg/ml (0.1 ng/ml; the concentration published to 
maintain hPSC pluripotency in suspension culture) the IL-6/sIL-6R fusion protein 
(Figure 3.9, blue line) seemed to have hardly any effect as nearly no phosphorylated 
Stat3 was detected. The relative amount of pStat3, indicated by OD 450nm Reading, 
at this concentration was already higher in hLIF treated cells (Figure 3.9, red line). 
Even in cells cultivated in the presence of IL-6 alone (Figure 3.9, green line), Stat3 
got phosphorylated at lower concentrations.  
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Figure 3.9: IL-6/sIL-6R fusion protein is less potent than hLIF or IL-6 alone 
HepG2 cells were treated with IL-6/sIL-6R fusion protein, hLIF and IL-6 for 6 hours; 
subsequently whole protein lysates were prepared. An ELISA for pStat3 shows that the 
fusion protein (blue) needs to be applied in higher concentrations to obtain the same level of 
pStat3 than IL-6 and hLIF 
 
When treated with 10 ng/ml of each molecule, the cell lysates contained 
approximately the same relative amount of pStat3, at 100 ng/ml a maximum was 
reached for all three Stat3 stimulators. This led to the conclusion that the IL-6/sIL-6R 
fusion protein is as potent in Stat3 activation as hLIF and as IL-6 alone.  
In total, two conclusions can be drawn from the experiments performed. First, the IL-
6/sIL-6R fusion protein is an agonist for LIF feasible to replace it. It seems not to be 
stronger, though, as the concentrations needed for Stat3 activation are even higher 
as the LIF concentrations. Second, the role of Stat3 downstream signaling still 
remains unclear. It was published that the IL-6/s-IL6R fusion protein can maintain 
pluripotency in hPSC suspension cultures. In the experiments described in this 
chapter, the fusion protein could not activate Stat3 downstream genes.  
In order to further investigate the role of the Stat3 signaling pathway in hPSC biology, 
it was decided to establish a loss-of-function model. 
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3.2 Loss-of-function of Stat3 signaling via genome editing 
Several techniques are known to edit the genome of cells. Since the TALEN 
technology was reported to be applicable for genetic engineering in hPSCs, this 
technology should be used to establish a targeted gene inactivation of Stat3 in 
hPSCs.   
 
3.2.1 Establishment of a TALEN pair against Stat3 
TALEN pairs can be designed to bind and cut at specific loci. Using a modular 
system, an assembly of a desired TALEN pair can be achieved by just using few 
special plasmids. The working group of Professor Hornung (Bonn University) 
established a system to clone TALEN constructs by using a pentamer library of the 
TALEN repeat units (Schmid-Burgk, 2013). 
The Hornung Lab kindly provided a TALEN pair against Stat3, namely 3L and 3R, 
which was shown to functionally edit the genome in the here not relevant cell system 
HEK 293T when transfected as plasmids. Functionality in hPSCs should be shown in 
this part of the thesis. All TALEN constructs hold a flag-tag enabling a read out of 
transfection and translation.  
As nucleofection via electroporation and lipofection did not lead to successful 
transfection of hPSCs with TALEN plasmids (for electroporation see Table 3.1), an 
mRNA synthesis was started. The target cells for the TALEN were supposed to be 
hPSCs; initial experiments had shown that hPSCs could be transfected efficiently 
with synthetic mRNA.  
 
Table 3.1: Overview of electroporation attempts 
 
Read-out for TALEN transfection was a T7-Assay, for GFP the presence of a fluorescence 
signal. Single cells (1x107) were electroporated in the indicated buffer and afterwards plated 
on MatrigelTM coated 6 well-dishes 
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3.2.2 Generation of TALEN mRNA 
The TALEN plasmids constructed by the Hornung Lab are designed in that way that 
a double digestion with two restriction enzymes leads to a construct in the form of 
5´UTR-TALEN-3`UTR. The construct has a size of approximately 3.4kb. After 
digestion, the fragments were separated by electrophoresis. The band at the height 
of 3.4kb was cut out and purified. To amplify this template, a template PCR was 
performed using a primer pair that binds in the 5´ and 3´ UTR (5´UTR fwd and 3´UTR 
rev). The efficiency of the PCR was checked on an agarose gel (see Figure 3.10). In 
case of the 3L construct, the template PCR was successful, as a band at the 
expected height could be seen. However, several additional bands could be seen 
that represent fragments of a smaller size. The PCR on the 3R construct led to 
similar results, as several unspecific bands occurred. The band on the expected size 
was much weaker, though. PCR conditions were adapted; because of the length of 
the TALEN constructs, the extension time was increased from 1 minute to 1:45 
minutes. This and the addition of DMSO led to a slight improvement of the PCR 
outcome. Nevertheless, the contamination of unspecific bands and the concentration 
of the desired PCR product were still not satisfying (Figure 3.10, A).  
The PCR product was used anyway as a template for the following tail PCR. The 
primers used in this PCR bind to the same sites of the DNA as the template PCR 
primer pair. The 5´UTR primer is exactly the same (5´UTR fwd), whereas the 3´UTR 
primer has a 120 base long T-tail (3´TailT rev). The fact that the primers bind to the 
same spots means that the tail PCR should amplify only the correct fragment of the 
template. The outcome again was poor (Figure 3.10, B). To get more tailed templates 
for the in vitro transcription (IVT), it was attempted to run the tail PCR directly on the 
fragment cut out from the plasmid. The tail PCR resulted in one prominent band at 
the height of the expected PCR product at around 3.4kb (Figure 3.10, C). This was 
unexpected, as the primers bind to the same region of the DNA. PCR conditions 
were the same as mentioned above, with elongated extension time and the addition 
of DMSO.  
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Figure 3.10: Amplification of two TALEN constructs (3L and 3R) 
Template PCR with the 5´UTR fwd and 3´UTR rev primer pair (A) results in a lot of additional 
bands, the PCR product with a size of 3.4kb can hardly be detected. Tail PCR does not 
succeed when the PCR product from (A) is used as a template (B). Tail PCR of the fragment 
of the digested plasmids using 5´UTR fwd and 3´TailT rev has the best outcome (C). 
 
As a conclusion, tailed templates for the IVT were generated by digesting the TALEN 
plasmids; the 5´UTR-TALEN-3´UTR fragment was purified and used as a template 
for the following tail PCR. Due to the large size of the construct, it was necessary to 
lengthen the extension phase and to add DMSO.  
In vitro transcription and capping was performed as described in 2.3.4. Afterwards, 
RNA gel electrophoresis should be performed to estimate the quality and purity of the 
synthetic mRNA. mRNA preparations showing a single sharp band at the correct 
height (>3kb) were considered to have a high quality. Only high quality mRNAs were 
used for transfections. Because denaturing gel electrophoresis had a very weak 
quality (data not shown), native gel electrophoresis was performed.  
 
Both synthetic 3L and 3R TALEN mRNA could be generated. IVT resulted in a single 
mRNA with a size of >3kb. The band on the gel was sharp, only a slight smear could 
be seen below the band, indicating that some smaller RNA fragments were 
synthesized or that mRNA molecules got degraded (Figure 3.11, A). 
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Figure 3.11: Stat3-TALEN mRNA were synthesized and translated by HEK 293T cells 
(A) Native gel electrophoresis shows an mRNA with a size of >3kb 
(B) Immunoblot: HEK293T cells were transfected with synthetic TALEN mRNA of both 3L 
and 3R construct; the TALEN mRNA that also encodes for a flag-tag was translated, 
indicated by the flag signal in the immunoblot. Development: SuperSignal West Femto 
Substrate 
 
In order to analyze whether the mRNA could be translated to proteins, Stat3-TALEN 
mRNA was transfected into HEK 293T cells. Per well of a 6 well plate, 1 #g of each 
TALEN mRNA was transfected. After 16 hours of incubation, medium was changed 
to culture medium. The cells were set to 37°C for 6 hours in order to recover, then 
transfection procedure was repeated. After a second incubation of 16 hours, whole 
cell protein lysates were obtained and separated with SDS-PAGE. In the immunoblot, 
a strong signal could be detected using a flag antibody (Figure 3.11, B). This 
indicates that TALEN mRNA could be transfected into HEK 293T cells. It gives also a 
hint about the quality of the mRNA, as the mRNA can be translated into protein in 
vivo.  
 
3.2.3 Functional TALEN mRNA can be transfected into different cell lines 
Even though the flag-immunoblot gave a hint about the quality of the TALEN mRNA, 
functionality still was not proven. To assess this, a T7 Assay was performed. For this 
assay, HEK 293T cells were transfected with both 3L and 3R TALEN mRNA and with 
one single TALEN mRNA (3L) alone as a control. As described before, transfection 
was performed twice, both times 1 #g of each mRNA was transfected.  
In case of successful transfection of both functional TALEN mRNA, the DNA should 
be cut at the target site. The DNA strand is repaired via NHEJ. In the T7 Assay, the 
T7 endonuclease recognizes non-perfectly matched DNA and cleaves it. Therefore, 
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in case of successful editing, the T7 Assay results in 2 bands, as the amplified target 
region is cut.  
HEK 293T cells were chosen as a first test cell line because it has been seen that 
they can be transfected very efficiently with synthetic mRNA.  
 
 
Figure 3.12: T7 Assay shows that Stat3 TALEN mRNA transfection leads to genome 
editing in HEK 293T cells 
Lane 1: Transfection of only one TALEN mRNA (3L) does not lead to editing of the Stat3 
gene as only a single band at the height of approximately 320bp can be detected.  
Lane 2: Transfection of both 3L and 3R TALEN mRNA results in restriction of the Stat3 gene 
at the target side, as indicated by the smaller fragments (arrows); densitometric quantification 
reveals an editing efficiency of 5%. 
 
As shown in Figure 3.12, the transfection of only one TALEN mRNA did not result in 
any cutting of the target side (lane 1). When both mRNAs of the TALEN pair were 
transfected, though, both TALEN could bind to the DNA and lead to an editing of the 
target side in the Stat3 gene, as indicated by the two smaller bands (arrows, lane 2). 
Quantification with ImageJ resulted in an efficiency of approximately 5%.  
As TALEN mRNA shall be used to manipulate hPSCs, it is necessary to show 
functionality of synthetic TALEN mRNA in hESCs or hiPSCs. First of all iLB-30-r12 
cells were transfected with 3L or 3R TALEN mRNA. Total cell protein lysates were 
analyzed for flag-tagged protein via immunoblot (Figure 3.13, A). This analysis 
demonstrated that 3L as well as 3R TALEN mRNA could be transfected into iLB-30-
r12 and were translated into TALEN proteins. To assess the functionality, hiPSCs of 
the line iLB-30-r12 were transfected with the 3L/3R TALEN pair and with the 3L 
alone. 
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Figure 3.13: Immunoblot and T7-Assay after transfection of TALEN mRNA into hiPSCs 
(A) Immunoblot against flag confirms transfection and translation of TALEN mRNA holding a 
flag-tag into hiPSCs; Development: SuperSignal West Femto Substrate 
(B) T7-Assay shows that, when transfected into hiPSCs of the iLB-30-r12 line, Stat3 TALEN 
mRNA led to editing at the target site (lane 2) indicated by a shortened band, whereas the 
control (3L only; lane 1) shows no effect. The efficiency of the editing is 5.1%.  
 
When transfected into the human iPSC line iLB-30-r12, the synthetic Stat3 TALEN 
mRNA led to a comparable result as in HEK 293T cells. They edited the target site 
with an efficiency of 5.1% (Figure 3.13, B, lane 2). Transfection of 3L TALEN mRNA 
alone did not result in restriction of the target side (Figure 3.13, B, lane 1).  
With the positive results of the T7 Assay, functionality of the synthetic TALEN mRNA 
has been proven. To further improve the outcome, transfection efficiencies of 
synthetic mRNA should be increased. To accomplish that, the effect of the 
modifications of synthetic mRNAs shall be tested.  
 
3.3 Innate immunity in hPSCs and their derivatives 
Standard protocols of mRNA synthesis require the use of at least two modified 
ribonucleotides, namely 5´methyl-CTP and pseudo-UTP (Warren et al., 2010). These 
modifications are claimed to reduce the response of the cell autonomous innate 
immunity upon mRNA transfection. When transfected with mRNA, cells normally 
react with the activation of the innate immune system, as mRNA resembles viral 
RNA. Due to the modifications of the synthetic mRNA, the cell cannot distinguish 
between synthetic mRNA and mRNA produced by the cell, resulting in higher viability 
of the cell upon transfection and an increased mRNA half-life. Initial results (data not 
shown) unexpectedly revealed that hPSCs could be transfected efficiently with 
modified as well as unmodified mRNA. To elucidate whether hPSCs do not require 
modified mRNA, two different synthetic GFP mRNA have been produced. First, the 
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standard protocol (Warren et al., 2010) was followed and the modified 
ribonucleotides 5´methyl-CTP and pseudo-UTP replaced CTP and UTP; this 
synthetic mRNA will be referred as “modified” (short: “mod”). Second, the unmodified 
ribonucleotides CTP and UTP were used; this synthetic mRNA will be referred as 
“unmodified” (short “unmod”). The capping protocol was followed for both synthetic 
mRNA types. 
 
 
Figure 3.14: Generation of two different synthetic GFP mRNA 
Lane 1: synthesis of modified GFP mRNA results in a single pure mRNA with the expected 
size of around 1000bp. Lane 2: unmodified GFP mRNA synthesis also give rise to a 
prominent mRNA of the expected size; several bands can be found in the lane indicating 
contaminating RNA fragments 
 
Modified as well as unmodified synthetic GFP mRNA could be generated (Figure 
3.14). On a native agarose gel, the modified GFP mRNA showed a single band at the 
expected height of 1000bp (Figure 3.14, lane 1). Unmodified GFP mRNA synthesis 
also resulted in a 1000bp-sized RNA, however some additional bands were detected 
exhibiting bigger sizes (Figure 3.14, lane 2). For both mRNA syntheses, the same 
template was used.  
 
3.3.1 hPSCs and lt-NES cells can be transfected with unmodified mRNA 
To confirm that hPSCs can be transfected with unmodified mRNA, hiPSCs of the line 
iLB-30-r12 and hESCs of the H9.2 and I3 lines were plated on 6-well dishes. 24 
hours later, they were transfected with 800 ng/well of modified mRNA or 800 ng of 
unmodified mRNA. As a control, cells were transfected with the same amount of 
polyA, a polynucleotide. The transfection reagent used was Lipofectamine® LTX. 16 
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hours after transfection, the transfection mix was exchanged with fresh medium and 
pictures have been taken to estimate the fluorescence. To facilitate comparison of 
the fluorescence intensities and efficiency of the transfection, the fluorescence 
pictures were taken using the same exposure time for each experiment.  
 
 
Figure 3.15: Transfection of unmodified GFP mRNA into hiPSCs results in a robust 
translation of GFP 
Transfection of iLB-30-r12 iPSCs with 800 ng of unmodified mRNA leads to a stronger 
fluorescence signal than with modified mRNA. 
Magnification: 40X; exposure time= 125ms 
 
The human iPSC line iLB-30-r12 could be transfected efficiently with modified and 
unmodified synthetic GFP mRNA. As it can be seen in Figure 3.15, both cells 
transfected with modified and unmodified mRNA survived mRNA transfection. The 
colonies have a similar size and a similar amount of debris is present in the 
supernatant, indicating no additional stress induced by unmodified synthetic mRNA. 
Transfection with unmodified mRNA seems to lead to stronger fluorescence intensity, 
which could be due to a better translation. Both fluorescence pictures depicted in 
Figure 3.15 were exposed for 125ms.  
A similar effect could be observed in H9.2 human embryonic stem cells (Figure 3.16); 
however, the effect was less striking as the difference between the fluorescence 
intensities of cells transfected with modified and unmodified GFP mRNA was not as 
strong as observed in iLB-30-r12 hiPSCs. Nonetheless, the transfection efficiency of 
unmodified GFP mRNA appeared to be higher. 
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Figure 3.16: Transfection of both modified and unmodified GFP mRNA leads to an 
intense translation of GFP 
The intensities of the fluorescence are on a comparable level for modified and unmodified 
GFP mRNA transfected into hESCs of the H9.2 line. Both mRNA can be transfected 
efficiently into the hESCs. 
Magnification: 40X; exposure time= 100ms 
 
 
With I3, another human embryonic stem cell line was tested. Transfection with either 
modified or unmodified mRNA (Figure 3.17) as well as polyA control (data not 
shown) resulted in decreased growing or increased dying of the cells as only little 
cells were attached after 16 hours of incubation with the transfection mix. In spite of 
this, the surviving cells were transfected with a high efficiency. The synthetic mRNA 
appeared to be translated very efficiently, as an exposure time of 75ms was sufficient 
to detect fluorescence in the modified mRNA transfected cells as well as the 
unmodified, which was even stronger (Figure 3.17).  
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Figure 3.17: hESCs translate both modified and unmodified synthetic GFP mRNA 
The hESC line I3 shows a similar transfection capability as iLB-30-r12 hiPSCs. The intensity 
of the fluorescence is stronger in case of unmodified mRNA transfection. Both mRNAs can 
be transfected very efficiently into the hESCs. 
Magnification: 40X; exposure time= 75ms 
 
In order to quantify the observed effects, flow cytometric analyses were performed. 
For that, the hiPSC line iLB-30-r12 and the hESC lines H9.2 and I3 were transfected 
as described before. For flow cytometry, cells had to be singularized.   
In Figure 3.18 exemplary histograms of the flow cytometry are shown. iLB-30-r12 
cells could be transfected with modified GFP mRNA with an efficiency of 51.9%. 
When transfected with unmodified mRNA, efficiency increased up to 64.5%. Notably, 
in the overlay the stronger intensity of the unmodified mRNA (blue line) compared to 
the modified mRNA (red line) can be seen as the blue curve shifts to the right 
compared to the red one. 
For H9.2, this is not true, which recapitulates the results seen in Figure 3.16. The 
intensities of both mRNA seem to be comparable, as both lines have the peak at the 
same point. Nevertheless, the efficiency of transfection with unmodified mRNA was 
higher (56.2%) than with modified mRNA (40.6%). 
The findings found for I3 hESCs via microscopy could be confirmed by flow 
cytometry as well (Figure 3.18). The blue line has its peak at the far right side of the 
histogram, indicating a stronger fluorescence than the cells transfected with modified 
mRNA, as its red line shows a peak more to the left. The efficiencies of transfection 
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were high, as it was expected after microscopic evaluation (Figure 3.17); transfection 
with modified mRNA resulted in an efficiency of 67.7%, the use of unmodified mRNA 
could increase the efficiency up to 78%. 
 
 
 
Figure 3.18: Increased efficiency and stronger GFP intensity after transfection with 
unmodified GFP mRNA in hPSCs 
Exemplary histograms show that the transfection efficiency rises from 51.9% to 64.5% (iLB-
30-r12), from 40.6% to 56.2% (H9.2) and from 67.7% to 78% (I3) when hPSCs are 
transfected with unmodified mRNA instead of modified mRNA. In the overlays, the blue line 
shows that the intensity is stronger in cells transfected with unmodified mRNA compared to 
modified mRNA (red line) 
Blue: unmodified; red: modified 
 
The results shown in Figure 3.18 are just exemplarily, as the histograms are shown 
only from single experiments. In total, hPSCs were transfected in seven individual 
experiments with modified and unmodified mRNA.  
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Figure 3.19: Transfection of hPSCs with unmodified mRNA leads to a significantly 
higher efficiency 
Seven individual transfection attempts result in a mean efficiency for transfection with 
modified mRNA of 41.83% (±18.44). Efficiency is increased up to 51.57% (±18.23%) for 
unmodified mRNA.  
n=7; *: p<0.05 according to a paired t-test 
 
These experiments resulted in an average transfection efficiency for modified mRNA 
of 41.83% (Figure 3.19). Transfection with unmodified GFP mRNA could be achieved 
with an average efficiency of 51.57%. The standard deviation of 18% in both cases 
was relatively high, but still a t-test resulted in a p-value lower than 0.05, as a paired 
t-test was performed. The variety between the efficiencies in the seven experiments 
was high, but the increase of the efficiencies when unmodified mRNA was 
transfected did always occur.   
Taken together, these results let suggest that hPSCs cannot only be transfected with 
unmodified synthetic mRNA, but that the efficiency is even increased when 
unmodified instead of modified mRNA is transfected. If this were due to a reduced 
innate immune system response, it would be interesting to investigate how 
derivatives of hPSCs react upon transfection with unmodified synthetic mRNA.  
In order to elucidate the immune status of hPSC-derivatives, lt-NES cells, which were 
differentiated from the iPSC line iLB-30-r12, were transfected with modified and 
unmodified GFP mRNA. Per well of a 6-well dish, 800 ng of the designated mRNA 
were transfected into lt-NES with Lipofectamine® LTX. As a control, 800 ng of the 
polyA polynucleotide were transfected (data not shown). 
16 hours after transfection, efficiency and intensity were approximated via 
fluorescence microscopy. 
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Figure 3.20: Transfection of unmodified GFP mRNA into lt-NES cells results in a 
robust translation of GFP 
Transfection of unmodified GFP mRNA shows higher fluorescence intensity. Efficiency 
appears to be higher for unmodified mRNA. 
Magnification: 40X; exposure time= 75ms 
 
lt-NES cells showed the same reaction as hPSCs upon transfection with unmodified 
GFP mRNA (Figure 3.20). Apparently, the fluorescence intensity of the cells 
transfected with unmodified mRNA once more was stronger. Efficiency seemed to be 
increased as well. The cells kept growing in the same instance, no increased cell 
death indicated by detached cells in the supernatant could be observed. 
Quantification with flow cytometry confirmed that the efficiency as well as the 
intensity increased when unmodified GFP mRNA was transfected (Figure 3.21). Flow 
cytometry revealed an efficiency of 23.1% for the modified mRNA, whereas the 
unmodified mRNA could be transfected with an efficiency of 38.3% into lt-NES cells. 
In the overlay, the blue curve, which represents the histogram for the cells 
transfected with unmodified mRNA, is shifted to the right, indicating a strong 
fluorescence intensity. 
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Figure 3.21: Increased efficiency and stronger GFP intensity in lt-NES cells after 
transfection with unmodified GFP mRNA  
lt-NES cells can be transfected more efficiently with unmodified GFP mRNA (38.3%) than 
with modified GFP mRNA (23.1%). The fluorescence intensity is stronger when lt-NES cells 
are transfected with unmodified mRNA as in the overlay the peak of the blue histogram 
(unmodified) is more to the right than the peak of the histogram of modified mRNA-
transfected cells (red).  
  
Transfection of lt-NES cells was carried out three times. The variety between the 
individual experiments was relatively high as indicated by the high standard deviation 
(Figure 3.22). Nonetheless, in each experiment the efficiency was higher when 
unmodified mRNA was transfected.  
 
 
Figure 3.22: Transfection of lt-NES cells with unmodified mRNA leads to an increased 
efficiency 
The mean transfection efficiency increases from 28.87% (±17.91%) for modified mRNA up to 
43.63% (±23.57%) for unmodified mRNA.  
n=3; error bars show standard deviation; n.s.: not significant; p= 0.06 according to a paired t-
test 
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The average efficiency for modified mRNA was 28.87%. It increased up to 48.63% 
for unmodified mRNA. Due to a p-value of 0.06, the increase of the efficiency upon 
transfection with unmodified mRNA can only be considered as a trend, as it is not 
statistically significant.  
 
3.3.2 hFBs cannot be transfected efficiently with unmodified mRNA 
hPSCs and lt-NES cells both could be transfected more efficiently with unmodified 
mRNA. So far it cannot be excluded that this effect was due to a better quality of the 
mRNA without modifications. To rule out that option, human fibroblasts should be 
transfected with both modified and unmodified mRNA. As fibroblasts are fully 
differentiated somatic cells, the working hypothesis suggests that they have an active 
innate immune system that distinguishes foreign mRNA from cell-autonomous 
mRNA. An activated innate immune system could lead to degradation of the 
potentially harmful foreign mRNA and therefore would lead to a decreased efficiency. 
To test whether this occurs in human fibroblasts, different human fibroblasts were 
transfected with modified as well as with unmodified GFP mRNA. 800 ng of the 
particular synthetic mRNA were transfected into the cells using TransIT® transfection 
reagent. 16 hours after transfection, a first evaluation was performed using 
fluorescence microscopy.  
Human CRL-2097 fibroblasts could be transfected efficiently with modified mRNA, 
whereas the efficiency decreased when the cells were transfected with unmodified 
mRNA (Figure 3.23). After transfection, the cells kept growing, but seemed to be 
stressed indicated by morphology. The amount of attached cells appears to be higher 
in case of transfection with modified mRNA. This effect was not quantified but could 
give a hint that the transfection with unmodified mRNA led to more frequent cell 
death.  
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Figure 3.23: CRL-2097 fibroblasts can be transfected more efficiently with modified 
GFP mRNA 
Transfection with modified GFP mRNA results in a higher efficiency and a stronger 
fluorescence intensity than transfection with unmodified mRNA. 
Magnification: 40X; exposure time= 915ms 
 
 
 
Figure 3.24: Transfection with modified GFP mRNA results in stronger fluorescence 
intensity  
Dravet fibroblasts can be transfected with modified mRNA more efficiently than with 
unmodified mRNA; the fluorescence intensity appears to be much higher. 
Magnification: 40X; exposure time= 2100ms  
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In case of the Dravet human fibroblast line (Figure 3.24), both modified and 
unmodified mRNA did not lead to a slowed-down proliferation of the cells as in both 
experiments as well as in the control (data not shown) cells were confluent 16 hours 
after transfection. Nonetheless, efficiency and intensity appeared to be higher when 
Dravet fibroblasts had been transfected with modified GFP mRNA.  
 
When quantified by flow cytometry, both Dravet and CRL-2097 fibroblasts showed 
similar results (Figure 3.25). Dravet fibroblasts could be transfected with modified 
GFP mRNA with an efficiency of 43.3%. When transfected with unmodified mRNA, 
efficiency decreased to 32.1%. Transfection of CRL-2097 fibroblasts with the 
modified version of the synthetic mRNA resulted in an efficiency of 79.6%, whereas 
the unmodified version could be transfected with an efficiency of 67%. 
 
 
Figure 3.25: Human fibroblasts can be transfected more efficiently with modified 
mRNA 
In this single experiment, transfection of fibroblasts with modified mRNA leads to an 
efficiency of 43.3% (Dravet FB) or 67% (CRL-2097). Transfecting the unmodified mRNA 
results in decreased efficiencies (32.1% for Dravet FB and 67% for CRL-2097). The overlay 
indicates that the fluorescence intensity for modified mRNA-transfected fibroblasts is 
stronger, as the red histogram (modified) is shifted more to the right than the histogram for 
the unmodified mRNA-transfected cells (blue histogram). 
 
In total, six independent transfections were performed and validated by flow 
cytometry. The variation between the experiments was very high, as the best 
transfection efficiency yielded 92% (CRL-2097 fibroblasts transfected with modified 
mRNA) and the lowest 23.2% (Dravet fibroblasts transfected with unmodified 
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mRNA). Despite of this, the experiments that were performed side-by-side always led 
to a reduced efficiency for unmodified mRNA transfection. Therefore, a paired t-test 
was performed to estimate the statistical significance. 
 
 
Figure 3.26: Human fibroblasts can be transfected more efficiently with modified GFP 
mRNA 
Transfection of modified mRNA results in an efficiency of 59.57% (±21.03%), unmodified 
mRNA can be transfected into fibroblasts with an efficiency of 42.08% (±30.51%). 
n= 6; error bars show standard deviation; *: p<0.05 according to a paired t-test 
 
The six independent experiments led to an average efficiency of 59.57% (±21.03%) 
for transfection with modified synthetic GFP mRNA. The average efficiency of 
transfection with unmodified synthetic GFP mRNA was around 17% lower (42.08% 
±30.51). Despite of the high standard deviation, a paired student t-test resulted in a 
p-value of 0.007, indicating that the decrease of efficiency is not a random effect but 
statistically significant (Figure 3.26).  
In Figure 3.27, the quantifications of the flow cytometric analysis are summarized. It 
can be seen that human pluripotent stem cells could be transfected more efficiently 
with unmodified than with modified mRNA; efficiency increased about 10% from 
41.83% to 51.57%. The difference between the results was statistically significant. 
Another significant effect could be observed for human fibroblasts; when transfected 
with unmodified mRNA, efficiency decreased from 59.57% to 42.08% around 17%. 
As a derivative of hPSCs, lt-NES cells could be transfected successfully with 
unmodified mRNA (43.63%), whereas the efficiency was 15% lower when modified 
mRNA was transfected (28.67%). The control cell line HEK 293T cell could be 
transfected at same efficiencies with modified as well as unmodified synthetic mRNA. 
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It showed the highest efficiencies with 86.7% (±9.9%) for modified and 85.7% 
(±10.32%) for unmodified mRNA.  
 
 
 
Figure 3.27: Summary of the flow cytometry quantification 
hPSCs can be transfected with unmodified mRNA with a significantly higher efficiency than 
with modified mRNA. Fibroblasts (hFB) show the opposite effect as transfection with 
unmodified mRNA leads to a significantly lower efficiency. Transfection of lt-NES cells can be 
increased when using unmodified mRNA; this effect is not significant, though. HEK 293T 
cells do not show different efficiencies for modified and unmodified mRNA. 
Light grey: modified; dark grey: unmodified 
n(hPSC)= 7, n(hFB)= 6, n(lt-NES)= 3, n(HEK293T)= 2; error bars show standard deviation;  
*: p<0.05 
 
 
The results presented in this chapter (summarized in Figure 3.27) let assume that 
pluripotent cells as well as multipotent precursor cells as lt-NES cells react differently 
upon transfection with synthetic mRNA without modifications compared to somatic 
cells. It was hypothesized that this was due to a reduced innate immune system 
activity.  
Results 
 
!85 
3.3.2.1 Inhibition of IFN" leads to increased efficiency 
To test whether the non-active innate immune system is responsible for the 
susceptibility of hPSCs to be transfected with unmodified mRNA, the role of one of 
the regulators of the innate immune system, the intracellular receptor TLR3, should 
be investigated. TLR3 activation results in IFN! signaling. If the innate immune 
system is responsible for the observed effects, inhibition of one of its activators 
should enable fibroblasts to be transfected with unmodified mRNA as well.  
 
 
Figure 3.28: Inhibition of IFN" leads to increased transfection efficiencies in human 
fibroblasts 
Untreated fibroblasts can be transfected with modified mRNA. Transfection with unmodified 
mRNA results in a low efficiency and weak fluorescence intensity. When treated with the 
IFN! inhibitor B18R (200 ng/ml), efficiency and intensity increase strongly for unmodified 
mRNA.  
Magnification: 40X; exposure time= 1600ms 
 
Dravet fibroblasts could be transfected with both modified and unmodified synthetic 
GFP mRNA (Figure 3.28), whereas the fluorescence intensity were decreased in the 
unmodified mRNA-transfected cells. When the fibroblasts were treated with the IFN! 
inhibitor B18R at a concentration of 200 ng/ml, intensity slightly increased for 
modified mRNA transfection. For unmodified mRNA transfection, the increase of both 
parameters was more prominent. 
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The quantification by flow cytometry showed a transfection efficiency of 53.3% for 
modified mRNA in CRL-2097. The efficiency reduced to 44.3% for unmodified 
mRNA. When CRL-2097 fibroblasts were treated with B18R, efficiency of unmodified 
mRNA transfection rose up to 63% (Figure 3.29). Treatment of B18R also led to an 
increased efficiency of modified mRNA-transfection for CRL-2097 fibroblasts (data 
not shown). 
For Dravet fibroblasts, a similar behavior could be observed. Modified mRNA was 
transfected into the cells with an efficiency of 46.4%; unmodified mRNA could only be 
transfected with 26% efficiency. Treatment with B18R led to an increase of efficiency 
for unmodified mRNA up to 60.6% (Figure 3.29).  
 
  
 
Figure 3.29: IFN" inhibition enables human fibroblasts to be transfected with 
unmodified mRNA 
CRL-2097 fibroblasts can be transfected with modified mRNA with an efficiency of 53.3% 
and with unmodified mRNA with an efficiency of 44.3%. Inhibition of IFN! by B18R treatment 
(200 ng/ml) leads to an increase of the unmodified mRNA transfection up to 63%. 
Dravet fibroblasts show a transfection efficiency with modified mRNA of 46.4%. Unmodified 
mRNA can be transfected into Dravet FB with an efficiency of 26%. Treatment with B18R 
improves the transcription efficiency of unmodified mRNA up to 60.6%. 
Red histogram: unmodified mRNA; blue histogram: unmodified mRNA with B18R treatment 
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Figure 3.30: Human fibroblasts can be transfected with unmodified synthetic mRNA 
with a higher efficiency when IFN" is inhibited 
Human fibroblasts can be transfected with modified GFP mRNA with an efficiency of 47.3%. 
Inhibition of IFN! with 200 ng/ml B18R does not lead to a notable change. Transfection with 
unmodified GFP mRNA results in an efficiency of 32.5%; efficiency is increased up to 
59.35% when cells were treated with B18R.  
n=2; error bars show standard deviation  
 
In summary (Figure 3.30), human fibroblasts could be transfected with modified 
mRNA with an average efficiency of 49.85% (±4.88%). The inhibition of the TLR3 
downstream effector IFN! led to contradictory results. The average transfection 
efficiency of modified mRNA with B18R treatment was 51.15%, which would mean 
that B18R had no effect on transfection, but the high standard deviation of 22.27% 
indicates the high variability. As described before, transfection of fibroblasts with 
unmodified mRNA was not as successful as it resulted in an average efficiency of 
35.15% (±12.94%) and thereby in a decrease of almost 15% compared to modified 
mRNA-transfection. Inhibition of IFN! led to an average efficiency of unmodified 
mRNA-transfection of 61.8% (±1.70%). Statistical analysis could not be performed as 
only two individual experiments were performed. Therefore it cannot be said whether 
the increase of transfection efficiency upon IFN! inhibition is statistically significant, 
but it gives a hint that the innate immune system plays a role in mRNA transfection 
into fibroblasts.  
 
To exclude whether this effect of B18R was not due to the inhibition of IFN! but a 
side effect, lt-NES cells and hPSCs were transfected with modified and unmodified 
mRNA while treated with B18R (200 ng/ml).  
As shown in Figure 3.31, no obvious effect could be detected by evaluation with 
fluorescence microscopy. Both lt-NES cells (Figure 3.31, A) and human iPSCs 
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(Figure 3.31, B) could be transfected more efficiently with unmodified mRNA and also 
gave a stronger fluorescence intensity. Treatment with B18R affected neither 
transfection with modified nor unmodified mRNA.  
 
 
Figure 3.31: IFN" inhibition has no effect on mRNA transfection into lt-NES cells and 
hiPSCs  
(A) lt-NES cells can be transfected more efficiently with unmodified mRNA than modified 
mRNA. The treatment with 200 ng/ml of B18R does not lead to an increase of efficiency or 
intensity. Exposure time= 90ms (B) Transfection of iLB-30-r12 human iPSCs with unmodified 
mRNA is more efficient than transfection of the modified mRNA. Inhibition of IFN! does not 
affect efficiency or fluorescence intensity. Exposure time= 120ms 
Magnification: 40X 
 
In summary, the fact that human fibroblasts cannot be transfected efficiently with 
unmodified mRNA seems to depend on an activated innate immune system. The 
inhibition of one of its regulator leads to an improved transfection with unmodified 
and therefore immunogenic mRNA. IFN! inhibition had no effect on hPSCs and lt-
NES cells, cells that are claimed to have no active innate immune system. 
 
 
3.3.3 hPSCs and lt-NES show less immune response upon transfection with 
unmodified mRNA than with modified mRNA 
To further elucidate the role of the innate immune system of hPSCs, its activation 
was analyzed via qRT-PCR for Interferon ! (IFN!). IFN! expression is upregulated 
upon TLR3 activation. Cells were transfected with 800 ng/well of a 6well dish of 
either modified or unmodified GFP mRNA. As a control, cells were transfected with 
800 ng/well of polyA, a polynucleotide that does not provoke immune reaction. Total 
RNA was isolated 6 and 24 hours after transfection and subsequently reverse 
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transcribed into cDNA. As illustrated in Figure 3.32 A and B, fibroblasts of two 
different lines showed a strong upregulation of IFN! expression when transfected 
with unmodified mRNA. Whereas the relative expression was increased 131 fold 
(CRL-2097) or 1602 fold (BJ) after 6 hours compared to polyA control, 24 hours after 
transfection the relative IFN! expression rose up to 5239 fold (CRL-2097) and 5606 
fold (BJ), respectively.  
 
 
Figure 3.32: IFN" expression is induced in fibroblasts more strongly than in PSCs and 
their derivatives 
(A)-(B) IFN! expression is induced strongly in human fibroblasts upon transfection with 
unmodified mRNA; relative expression increases with time. (C) hESC line I3 does not react 
with increased IFN! expression upon mRNA transfection. (D) hiPSC line iLB-30-r12 
expresses IFN! after transfection with unmodified mRNA, but to a less extent than human 
fibroblasts; after 24 hours, IFN! expression is strongly reduced. (E) lt-NES cells derived from 
the iLB-30-r12 line do not react to a notable extent to mRNA expression. Results were 
normalized against GAPDH. All RT-PCRs were performed in triplicates; error bars show 
standard deviation. Control (transfection with polyA) was set as 1. 
 
Notably, the immune reaction upon transfection with modified mRNA did not lead to a 
strong upregulation of IFN! expression. CRL-2097 fibroblasts did not react with IFN! 
expression, as its relative expression was only 1.69 after 6 hours and even below 1 
(0.87) after 24 hours (Figure 3.32, A). BJ fibroblasts, however, expressed IFN! after 
transfection with modified mRNA; with a relative expression of 33.07 after 6 hours 
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and 275.33 after 24 hours the immune response obviously is weaker than the one 
induced by unmodified mRNA (Figure 3.32, B).  
The hESC line I3 showed no upregulation of IFN! expression upon mRNA 
transfection, neither with modified nor with unmodified nucleosides (Figure 3.32, C). 
All relative expression values were below 1, suggesting no activation of the innate 
immune system. In contrast, hiPSCs of the iLB-30-r12 line showed an upregulation of 
IFN! expression upon transfection with unmodified mRNA (Figure 3.32, D). With a 
relative value of 498 the upregulation was only a tenth as strong as in fibroblasts. 
Interestingly, the upregulation could be detected already after 6 hours and was 
reduced to 17 after 24 hours. In fibroblasts, the IFN! expression 24 hours after 
transfection was higher than 6 hours after transfection.  
 
In summary, it can be concluded that the TLR3 mediated immune response, 
indicated by Interferon ! expression, is reduced in hPSCs, as they do not respond 
strongly upon transfection with synthetic mRNA generated with unmodified 
nucleosides. lt-NES cells, as a derivative of hPSCs, were also transfected with 
modified and unmodified mRNA as well as polyA control (Figure 3.32, E). Consistent 
with the findings in GFP transfection, immune response could better be compared 
with hPSCs than with somatic fibroblasts. IFN! expression was only upregulated 1.6 
fold upon transfection with unmodified mRNA. These data suggest that lt-NES cells 
maintain the immunogenic status of pluripotent cells.  
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4 Discussion 
Human pluripotent stem cell biology is a fascinating field of research. The capacity of 
hPSCs to self-renew indefinitely while being able to differentiate into every cell of the 
body turned them into the focus of life sciences. The major disadvantage of hPSCs, 
namely the ethical limitations, could be circumvented by the technique of 
reprogramming, which was published 2007 for human cells and honored with the 
Nobel prize in 2012. Reprogramming facilitated the research on hPSCs. Still, a lot of 
research has to be done to gain an insight into the biology of human pluripotent stem 
cells. In this thesis, two general aspects of stem cell biology were investigated. First, 
the role of the Stat3 signaling pathway in human PSCs was analyzed, as it is a key 
signaling pathway in murine PSCs and understanding its role in human cells could 
eventually elucidate the differences between PSCs of the two different species. While 
performing the experiments, another interesting aspect of stem cell biology came up. 
As human PSCs could be transfected efficiently with synthetic mRNAs lacking 
modifications, it was hypothesized that the innate immune system of hPSCs differs 
from somatic cells.  
 
4.1 Human pluripotent stem cells do not depend on Stat3 signaling 
In 2004, Dahéron and colleagues published that LIF/STAT3 signaling is not able to 
maintain hESC pluripotency (Dahéron et al., 2004). Several working groups 
confirmed this finding (Humphrey et al., 2004; Sato et al., 2004). Before Dahéron and 
Sato investigated the role of Stat3 signaling more in detail, there were only anecdotal 
reports about the role of Stat3 signaling in human PSCs. In some publications it was 
suggested that LIF is not sufficient to maintain pluripotency (Reubinoff et al., 2000; 
Thomson et al., 1998), whereas another publication claimed that LIF helps to retain 
hESC pluripotency (Schuldiner et al., 2000). LIF signaling can have a positive 
influence on human embryos, as its activity has been reported to enhance human 
blastocyst formation in vitro (Dunglison, Barlow, & Sargent, 1996).  
The reason why Stat3 signaling was investigated again in this thesis is a publication 
that claimed that a potent agonist of LIF, the chimeric fusion protein of Interleukin-6 
and its soluble receptor (IL-6/sIL-6R), was able to maintain hPSC pluripotency in 
suspension culture in absence of feeder cells or conditioned medium (Amit et al., 
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2010). In this thesis, this should be transferred to and comprehensively investigated 
in adherent cultures. hPSCs were cultured as described in the published protocol 
(Amit et al., 2011), but instead of in bacteriological dishes on Matrigel™ coated cell 
culture dishes to allow attachment of the cells. The medium applied was the same as 
published, which equals standard culture medium for hPSCs cultivated on a feeder 
layer, containing serum replacement and bFGF. Due to the lack of feeder cells, 
Activin A was not present in the medium. The chimeric fusion protein could not 
prevent differentiation of the cells. While one day after medium change the cells 
revealed a pluripotency-associated morphology, meaning a compact colony structure 
with sharp borders, two days after switching the medium all hPSCs showed a 
morphology typical for spontaneous differentiation (see Figure 3.3). On the one hand, 
this effect is remarkable. The morphology differed strikingly from the negative control. 
On the other hand, the effect was just temporary, which makes it hard to explain.  
Due to the differentiation, Matrigel™ was not the optimal substrate anymore, 
therefore the cells detached and could not be kept in long-term cultures. The reason 
why the differentiation process was delayed in the presence of IL-6/sIL-6R is not 
known. Notably, not only the chimeric fusion protein, but also hLIF, had the effect of 
the delayed differentiation. Thus, if the observed effect is Stat3 signaling-dependent, 
the fusion protein seems not to be more efficient in the applied concentrations to 
activate the pathway.  
The analysis of total protein lysates of I3 hESCs revealed that 200 pg/ml of the fusion 
protein was not able to phosphorylate Stat3 in hPSCs, whereas hLIF treatment (10 
ng/ml) resulted in a weak activation of Stat3 (see Figure 3.4). Two target genes of 
Stat3 signaling, Socs3 and Pim1, were analyzed via qRT-PCR. The relative 
expression was lower than in the control cells cultivated under feeder-free conditions, 
even for a fusion protein concentration of 10 ng/ml. Therefore, even at concentrations 
as high as the hLIF concentration, the fusion protein was not able to induce Stat3 
signaling. In the published protocol, 100 pg/ml of the fusion protein are sufficient to 
maintain hPSC pluripotency. Unexpectedly, the expression of the target genes did 
even decrease upon IL-6/sIL-6R treatment. This could imply even an inhibition of 
Stat3 signaling by the chimeric fusion protein. But as the decrease is only slightly (up 
to 4 fold) and is not dose-dependent (see Figure 3.5), this is not likely. In order to 
confirm that Stat3 signaling is not activated upon IL-6/sIL-6R treatment, the 
expression of several other target genes should be analyzed.   
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Taken together, IL-6/sIL-6R as well as hLIF was not able to robustly phosphorylate 
Stat3 in hPSCs. This could be due to missing receptors or signal-transducers. LIF 
binds to the LIF receptor (LIFR), whereas the fusion protein does not need any 
receptor, but needs to bind to the signal-transducing transmembrane protein gp130.  
After LIF has bound to the LIFR, it dimerizes with gp130 and starts the Stat3 
signaling cascade. Therefore, LIF signaling requires the expression of both LIFR and 
gp130, whereas the induction of Stat3 signaling via IL-6/sIL-6R only needs 
expression of gp130. The weak, but present, phosphorylation of Stat3 in hPSCs upon 
hLIF treatment (see Figure 3.4) suggests that gp130 is present on the surface of 
hPSCs. Several reports support this suggestion. Humphrey et al. published that 
hESCs do express gp130 (Humphrey et al., 2004). In another study it was shown 
that hESCs express gp130 as well as LIFR (Dahéron et al., 2004). This is consistent 
with the findings presented in this thesis, as LIF is able to induce Stat3 activation, 
even if it is very weak, but contradicted by another publication reporting that LIFR is 
not expressed on hESCs (Rose-John, 2002).  
Chan et al., however, reported that gp130 is only poorly expressed in hPSCs. 
Interestingly, when hPSCs were cultured in LIF presence while inhibiting MAPK/ERK, 
Wnt and BMP signaling, the gp130 expression was upregulated. This led to the 
induction of a pluripotency state more closely to naïve pluripotency, as the cells 
survived dissociation in absence of ROCK inhibitor and the epigenetic status 
resembled the status of in vivo preimplantation epiblast cells (Chan et al., 2013). This 
suggests that the extent of gp130 on hPSCs is not sufficient to induce Stat3 signaling 
activity. For murine PSCs it is known that there is a threshold for the activity of Stat3 
to completely maintain their undifferentiated state (Ernst, Oates, & Dunn, 1996; 
Matsuda et al., 1999; Viswanathan et al., 2002).  
Still, it is possible that not the lack of LIFR and/or gp130 is the reason for the 
deficiency to respond to Stat3 signaling stimulators. Dahéron et al. showed in their 
report that Stat3 can be phosphorylated in hPSCs; furthermore activated Stat3 
dimerizes and translocates to the nucleus (Brierley & Fish, 2005; Dahéron et al., 
2004). This would suggest that other mechanisms, for example occupation of the 
pStat3-dimer binding sites in hPSCs, prevent activation of Stat3 target genes. 
Supporting this hypothesis, in this thesis it has been shown that Stat3 indeed can be 
phosphorylated in hPSCs without affecting target gene expression. 
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In conclusion, the knowledge in the field of Stat3 signaling in hPSCs consists of 
many ambiguous facts; further elucidation is needed.  
 
The activity of the chimeric fusion protein could not be confirmed to be higher than 
that of LIF or IL-6 alone. In the published protocol for suspension culture of hPSCs, a 
concentration of 100pg/ml was sufficient to maintain pluripotency (Amit et al., 2011). 
In mPSC culture, IL-6/sIL-6R could replace LIF only in high concentrations (10ng/ml; 
see Figure 3.7 and 3.8). This may be due to the fact that the fusion protein is a 
human recombinant protein. Therefore, the human cell line HepG2, which can have 
an active Stat3 signaling, was used as a model as the cells express LIFR as well as 
IL-6R and gp130 (Lütticken et al., 1994). Even in these cells the fusion protein was 
not able to phosphorylate Stat3 at lower concentrations (see Figure 3.9). A report 
from 1996 gives a hint why the chimeric fusion protein is not that active in Stat3 
phosphorylation. Ernst et al. published data that suggests that gp130 homodimers, 
as assembled when the fusion protein binds to gp130, have weaker effects on Stat3 
signaling than LIFR/gp130 heterodimers (Ernst et al., 1996). Given that fact, the use 
of the chimeric fusion protein would only be useful to activate Stat3 signaling in cells 
that do not express LIF receptor. However, the concentrations need to be high to 
gain a proper activation.  
Taken together, the results presented in this thesis together with the literature lead to 
two suggestions: first, the IL-6/sIL-6R chimeric fusion protein in the adherent culture 
is not as potent in pluripotency maintenance as described by Amit et al. for 
suspension culture, and second, the Stat3 signaling pathway seems to play no role in 
primed hPSCs. All obtained results need to be confirmed for other primed hPSC 
lines.  
The role of Stat3 signaling in naïve human stem cells will most likely play a different 
role. Therefore, the investigation of its activation in human naïve pluripotent cells 
would be interesting. Furthermore, the transition of both states in the aspect of Stat3 
signaling would be of interest.  
 
4.2 A TALEN-mediated inactivation of the Stat3 gene 
To further elucidate the role of Stat3 signaling, a TALEN pair has been established to 
generate a double strand brake in the Stat3 gene and therefore induce a gene 
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inactivation. The TALEN pair was constructed in the Hornung lab, where the 
plasmids were also tested for their functionality in HEK293T cells. Initial experiments 
to nucleofect the plasmids into hPSCs failed. It was reported that TALEN plasmids 
can be introduced into hPSCs via electroporation (Hockemeyer et al., 2011). Neither 
using the published protocol nor the establishment of an own protocol led to targeting 
of the Stat3 locus in hPSCs. Furthermore, most of the cells died (data not shown). 
Establishment of the protocol using a plasmid encoding for a fluorescent protein 
facilitated the validation of the experiments, but did also not result in functional 
protocols (data not shown). The reasons for that could not be determined, as also 
published electroporation protocols for hPSCs were adapted (Costa et al., 2007).  
hPSCs are a highly fragile system. A lot of parameters influence the health and 
survival of the cells. For example, the hPSCs used in successful electroporation 
attempts were cultivated on a feeder layer (Costa et al., 2005; Hockemeyer et al., 
2011b; Zwaka & Thomson, 2003). This could have led to an increased survival after 
transfection. Electroporation stresses the cells to a high extent (Stacey, Ross, & 
Hume, 1993). For electroporation, a single cell suspension is needed; hPSCs survive 
dissociation only when the Rho kinase is inhibited (Watanabe et al., 2007). Even in 
the presence of the ROCK inhibitor, dissociation leads to additional stress for hPSCs. 
Furthermore, electroporation requires a large amount of DNA and a lot of cells (Costa 
et al., 2007; Ding et al., 2013; Hanna et al., 2010).  
Therefore, it was decided to assess a different approach to transfect cells with 
TALENs. As preliminary experiments showed good results for the transfection of 
hPSCs with synthetic mRNAs, and it was also published that hPSCs can be 
transfected and manipulated with synthetic mRNAs (Warren et al., 2010), TALEN-
encoding mRNAs should be generated. Until then, only few reports have been 
published that make use of synthetic mRNAs encoding for TALENs. One group 
generated synthetic TALEN mRNA and injected it into zebrafish embryo (Dahlem et 
al., 2012). More recently, another group succeeded in inducing a double strand break 
at the Satb1 locus and introduced sequences of a target construct via homologous 
recombination by transfecting TALEN mRNAs together with the target construct into 
the nuclei of mouse pronuclear-stage embryos (Sommer et al., 2013). This data 
encouraged the hope that also hPSCs can be transfected with synthetic TALEN 
mRNA.  
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The protocol for synthetic TALEN mRNA generation followed the standard protocol 
for synthetic mRNA production. Surprisingly, template PCRs on the digested TALEN 
plasmid did not result in an amplification of the template (Figure 3.10 A). This was 
surprising, because the primer pair binds to the untranslated regions (UTRs) and is 
used for the synthesis for the template of every RNA. Therefore, the primers cannot 
be the reason for the failed PCR. As the TALEN construct is relatively long (3.4kb) 
and normally shorter mRNAs are synthesized (approximately 1kb), PCR conditions 
were adapted; elongation time was increased and DMSO was added. As this did not 
result in the desired improvement, as an alternative the 5´UTR-TALEN-3´UTR 
construct obtained via digestion of the TALEN plasmid directly was used as a 
template for the tail PCR without further amplification. Unexpectedly, tail PCR 
succeeded, as gel electrophoresis revealed a prominent band at the expected size of 
>3kb (Figure 3.10 C). This was unexpected since the primers bind to the same sites 
and the PCR conditions were equal. Even though there were some additional bands 
visible in gel electrophoresis, the tail PCR product was used as a template for the in 
vitro transcription (IVT). The reason for the overall poor outcome of the PCRs (Figure 
3.10 A-C) could be the highly repetitive modular structure of the TALENs. It can be 
hypothesized that the polymerase has difficulties in reading and polymerizing the 
repetitive structures. This would suggest that also the T7 polymerase, which is used 
for IVT, could have problems in reading and transcribing the repetitive template. In 
the first attempts of TALEN mRNA synthesis, a lot of smaller RNAs could be 
detected on the agarose gel (data not shown). After adjusting the IVT conditions 
(increasing the temperature from 37°C to 42°C; extending the incubation time from 
45 minutes to 60 minutes), a single prominent band could be detected when 
analyzed on an agarose gel. A slight signal could be observed around the expected 
band (see Figure 3.11 A); this could be due to degradation, as instead of denaturing 
gel electrophoresis a native gel electrophoresis was performed.  
Control transfection of the TALEN mRNA was performed into HEK293T cells. As the 
TALEN constructs also contain a flag tag, immunoblot with an antibody against flag 
could confirm the efficient transfection. Furthermore, the translation of the mRNA was 
proven (Figure 3.11 B). Moreover, a T7 Assay revealed functionality in HEK293T 
cells (Figure 3.12). The mutation frequency achieved in HEK293T cells was 5%. This 
efficiency is relatively low, if one expects that HEK293T cells can be transfected with 
mRNA with a high efficiency. Considering that two mRNAs have to be transfected 
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into the cells, it still is a low efficiency. This could indicate a poor quality in either 
purity or assembly of the TALEN mRNA. Given the problems during template 
generation and IVT, the obtained synthetic mRNAs could be partially not functional, 
for example when not been transcribed from a full-length template. Additionally, the 
size of the TALEN mRNA with more than 3 kilobases could lead to problems during 
transfection. Also, the concentrations could need to be adapted, as due to the length 
of the TALENs, 1#g of RNA equals less mRNA molecules for TALEN mRNA than for 
example for GFP mRNA. Subsequently it was shown that TALEN mRNA can also be 
transfected into hPSCs. Human iPSCs from the iLB-30-r12 line were successfully 
transfected with both mRNAs (see Figure 3.13 A). iLB-30-r12 cells translated the 
synthetic mRNAs to functional TALENs indicated by an editing efficiency of 5.1% 
(Figure 3.13 B). As transfection of hPSCs is harder to achieve, transfection protocols 
still can be optimized to increase the mutation frequency. A possible way to improve 
mRNA transfection, namely the use of unmodified synthetic mRNAs, was not 
investigated due to time reasons. 
With the results in this thesis, a proof-of-principle was accomplished that the genome 
of hPSCs can be engineered with synthetic TALEN mRNAs. To examine an effect of 
the Stat3 inactivation, clonal populations of hPSCs should be generated after TALEN 
transfection. Subsequently, a T7 assay could reveal the clones positive for Stat3 
editing. These cells could be propagated further and used for further analysis.  
 
4.3 Synthetic mRNAs are a robust tool to manipulate hPSCs  
As described before, it was not possible to transfect hPSCs with plasmid DNA using 
electroporation during the experiments for this thesis. As the generation of a 
corresponding synthetic mRNA as well as the transfection of this mRNA into hPSCs 
succeeded, it is claimed that synthetic mRNAs are a feasible tool to manipulate 
hPSCs. The use of synthetic mRNAs to manipulate cells has the advantage that its 
short half-life and quick translation results in a tight control over application times. No 
integration into the host genome can occur, as it would be the case for DNA based 
approaches.  
As the targeting efficiency of the TALEN mRNAs (as described in 4.2) was relatively 
poor, an optimization of mRNA quality could improve the outcome. Warren et al. 
transfected human cells with synthetic mRNAs in order to reprogram them into 
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pluripotent stem cells; furthermore, they used synthetic mRNAs to induce directed 
differentiation of hPSCs (Warren et al., 2010). However, they did not report 
transfection efficiencies of mRNAs into hPSCs, which might be of interest for further 
applications. Warren et al. worked with modified mRNAs, as it was reported that the 
modifications of synthetic mRNA reduce the innate immunity activation (Karikó et al., 
2008, 2005; Nallagatla & Bevilacqua, 2008). Posttranscriptional modification of RNA 
is a process frequently found in vivo. Nearly 100 different nucleoside modifications 
are known (Cantara et al., 2011). Transfer RNA is the RNA subgroup most heavily 
modified, up to a quarter of the nucleosides are modified. Mitochondrial RNA has 
fewer modifications, as this organelle is a relic of eubacteria (Margulis & Chapman, 
1998).  
The lack of modifications leads to a resemblance of synthetic mRNA to viral RNA. 
Viral RNAs, whether single- or doublestranded, function as PAMPs and get 
recognized by PRRs. For example, the toll-like receptors TLR3, TLR7 and TLR8 
recognize viral mRNA (Karikó et al., 2005, 2004).  
Furthermore, RIG-I binds viral RNA and subsequently activates an innate immune 
response (Uzri & Gehrke, 2009; Yoneyama et al., 2004).  
Two groups published successful generation of functional TALEN mRNAs; in the 
published studies, TALEN mRNAs were generated without employing the modified 
ribonucleoside bases (Dahlem et al., 2012; Sommer et al., 2013). In both cases, 
mRNAs were injected directly into embryos. Together with the known attenuated 
innate immunity of the embryo in the sterile environment of the womb (Levy, 2007), 
this led to the hypothesis that hPSCs can be transfected with unmodified mRNAs. In 
order to improve transfection and translation, the efficiencies of unmodified mRNAs 
should be tested. 
4.4 Modified versus unmodified mRNA 
The generation of unmodified mRNAs has the advantage that it is less cost intensive, 
as the modified ribonucleotides are relatively expensive compared to the unmodified 
standard ribonucleotides. As mRNA in vivo also gets modified, the effect of the 
withdrawal of modifications was subject of this thesis. To have a direct insight into 
transfection efficiencies, synthetic GFP mRNA was used. First of all, modified as well 
as unmodified GFP mRNA was generated. Both IVTs were performed using the 
same batch of template; synthesis was performed side-by-side with the same 
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aliquots of each reagent to exclude batch-variant differences. After gel 
electrophoresis, both synthetic GFP mRNAs showed one prominent band with the 
expected size of 1kb. Interestingly, in the lane of unmodified mRNA (see Figure 3.14, 
lane 2), additional bands with a smaller size could be detected. The bands were 
much weaker than the GFP band, but they were from defined lengths. This effect 
could be observed in three independent in vitro translations of unmodified mRNA, but 
never for modified mRNA. The reasons for that are not known. Vertebrate cells do 
synthesize modified mRNAs, but the modifications are posttranscriptional (Garcia & 
Goodenough-Lashua, 1998). The usage of modified ribonucleotides therefore is not 
likely to be the reason for the improved synthesis of mRNA. The in vitro transcription 
kit used in this thesis depends on a RNA polymerase of the T7 bacteriophage. In T7 
phages, no modifications of RNA have been reported. Therefore, an improved mRNA 
synthesis in the presence of modified ribonucleotides cannot be due to a better 
performance of the T7 polymerase.  
The only different components used for modified mRNA were pseudo-UTP instead of 
UTP and 5´methyl-CTP instead of CTP. To exclude that a bad quality of this 
component leads to the different outcome of IVT, two different batches of nucleotides 
were used leading to no difference. So, the reason for additional bands for 
unmodified synthetic GFP mRNA could not be detected.  
 
In this thesis, the modified mRNA was synthesized using pseudoUTP and 5-methyl-
CTP. These are modifications unique for mammalian RNA, as pseudouridine is a 
known component of ribosomal RNA (Sumita et al., 2005), and 5-methylcytidine is 
found in mammalian in vivo mRNA (Sibbrit, Patel, & Preiss, 2013). Since these 
nucleoside modifications play a role in distinguishing host from foreign RNA, the 
innate immune system may play a role leading to the different results obtained with 
modified and unmodified mRNA. hPSCs could be transfected more efficiently with 
unmodified than with unmodified mRNA. Somatic cells, represented by human 
fibroblasts, could not be transfected efficiently with mRNAs lacking the modifications, 
suggesting that these cells express the modulators of a functional innate immune 
system. The control cell line HEK293T could be transfected with modified as well with 
unmodified mRNA efficiently. HEK293T cells are obtained from kidney tissue. The 
fact that they have a chromosomal number of 64 and are immortal reveals their 
mutated genotype. Therefore, even if kidney tissue normally would have an innate 
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immunity, the abnormality of HEK293T could be responsible for the lack of immune 
response upon transfection with unmodified mRNA. Interestingly, lt-NES cells, the 
derivatives of the human iPSC line iLB-30-r12, could be transfected with unmodified 
mRNA more efficiently than with modified mRNA, and therefore seem to resemble 
pluripotent stem cells in their immunogenic potential. 
 
Interestingly, the transfection of hPSCs and lt-NES cells with unmodified GFP mRNA 
resulted in a stronger fluorescence than modified mRNA. As mentioned before, 
mRNAs are modified in vivo as well, partly even with the same modifications used in 
this thesis. Thus, the modifications of the nucleotides should not lead to decreased 
translation efficiency. Another possible reason for the stronger fluorescence in case 
of unmodified mRNA could be a better quality of the unmodified mRNA. This can be 
excluded, as gel electrophoreses revealed an even slightly worse quality of 
unmodified mRNA. Moreover, both reasons would also lead to a stronger 
fluorescence intensity in fibroblasts.  
The fact that hPSCs and lt-NES cells can be transfected more efficiently with 
unmodified GFP mRNA compared to modified GFP mRNA, is also displayed by the 
fact that the intensity of the fluorescence is higher. This could indicate that the 
transfected cells translated more mRNA molecules. Nonetheless, it would be 
puzzling why not more cells were transfected with mRNA, as the transfection 
efficiencies did not reach more than 78.00% (average transfection efficiency 
51.57%). If the transfection mix contains that many mRNA molecules that several 
molecules enter one cell, it should be enough to transfect more cells. However, this 
relatively low average efficiency could be due to the accessibility of the cells. During 
growth, hPSCs form colonies. So it cannot be excluded that cells are in the center of 
such a forming colony and therefore having a small surface enabling transfection. 
The same is true for lt-NES cells that form rosettes during growth. A further reason 
for the efficiency could be the dependency of the cell cycle. It was reported that cells 
can not be transfected with lipoplexes during G1-phase (Brunner et al., 2000). As 
hPSCs and lt-NES cells are highly proliferative, a relatively large proportion of cells 
might be in G1-phase and thus not be accessible for transfection. To confirm this, the 
transfection could be repeated 6 hours later; the cells then should be accessible, 
which would result in a higher overall eifficiency. 
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Nonetheless, the reasons for the better transfection efficiency and stronger intensity 
of unmodified mRNA in hPSCs are not revealed. In the literature it was described 
that the use of pseudouridine in mRNA synthesis led to a superior translation in 
mammalian cells and when injected into mice (Karikó et al., 2008). This is consistent 
with the findings presented in this thesis for fibroblasts, which are somatic cells. In 
contrast, hPSCs as well as lt-NES cells showed a stronger translation when 
transfected with unmodified mRNA, suggesting that the observed effect is specific for 
stem and precursor cells. 
A shift to the right of the histogram in flow cytometric analysis led to the interpretation 
that the translational efficiency was higher. Remarkably, in case of hPSCs also the 
negative cells were shifted to the right when transfected with unmodified mRNA (see 
Figure 3.18). So this effect could also be due to background fluorescence. 
 
4.5 Innate immunity is attenuated in hPSCs 
The observation that human pluripotent stem cells can be transfected efficiently with 
unmodified mRNA whereas somatic fibroblasts could be transfected with modified 
mRNA more efficiently, resulted in the hypothesis that the innate immune system of 
hPSCs is attenuated. It is known that the distinction between host and foreign RNA 
through its modifications is mediated by TLR3, a receptor of the innate immune 
system (Karikó et al., 2005). Nonetheless, the activation of the innate immune 
system upon transfection with both forms of mRNA had to be investigated to confirm 
the contribution of the innate immune system.  
As a first experiment, human fibroblasts were treated with B18R during transfection. 
B18R is an inhibitor of Interferon signaling. Interferon ! is stimulated upon TLR3 
activation (Oshiumi et al., 2003). If recognition of unmodified mRNA would induce 
TLR3 mediated Interferon ! activation, a treatment with B18R would prevent the 
transmission of this signal. Indeed, fibroblasts treated with B18R could be transfected 
more efficiently with unmodified mRNA compared to untreated cells (see Figures 
3.28, 3.29 and 3.30). The efficiency was even higher than with modified mRNA. One 
reason for that could be that also modified mRNA provokes an immune response that 
however is lower than for unmodified mRNA. This is challenged by the fact that B18R 
treatment did not lead to an increased efficiency for modified mRNA transfection. 
B18R was used to enhance cell survival during mRNA mediated reprogramming by 
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Warren et al. In this study modified mRNAs were transfected, indicating that B18R 
and thus Interferon signaling can have an effect also on transfection with modified 
mRNA (Warren et al., 2010).  
Expectedly, B18R treatment had no effect on mRNA transfection into hPSCs and lt-
NES cells (see Figure 3.31). This supports the hypothesis that these cells do not 
activate the innate immune system upon mRNA transfection. Therefore, an inhibition 
of Interferon signaling does not lead to a further increase of transfection efficiency.  
It may also be possible that the innate immune system in hPSCs upon RNA 
transfection is activated through another receptor. Another member of the toll-like 
receptor family, namely TLR7, also senses for infections with single stranded RNA 
(Diebold et al., 2004). Upon activation, TLR7 induces Interferon $ (IFN$) expression 
and thus innate immunity activation. As nothing is known about the expression of 
TLR7 in hPSCs, the role of TLR7 in its attenuated innate immunity has to be 
investigated.  
To confirm the role of Interferon signaling in mRNA transfection, qRT-PCRs were 
performed to analyze the expression level of Interferon !. An upregulation would 
suggest an increased innate immune response.  As expected, two different human 
fibroblasts reacted with an upregulated IFN! expression upon transfection with 
unmodified mRNA (see Figure 3.32 A, B). The IFN! expression was increased 
131fold or 1602fold respectively after 6 hours, but to a greater extent after 24 hours 
(more than 5000fold for both cell lines). The transfection with modified mRNA did not 
result in a strong upregulation of IFN! expression; in CRL-2097 no effect could be 
observed, whereas BJ fibroblasts upregulated IFN! expression 275fold 24 hours 
after transfection. Compared with the reaction on transfection with unmodified 
mRNA, the response evoked by modified mRNA is very low. In conclusion, 
unmodified mRNA activates the innate immune system of fibroblasts, as Interferon ! 
expression is upregulated. Surprisingly, the induction of IFN! expression could be 
detected only 24 hours after transfection. Six hours after transfection, no strong effect 
on IFN! expression could be detected. A further investigation of the time course of 
IFN! upregulation could give insights into the velocity of innate immunity activation 
and duration of the response.  
In case of hPSCs, one hESC line (I3) and one hiPSC line (iLB-30-r12) were tested 
(see Figure 3.32 C, D). In I3 cells, the IFN! expression upon mRNA transfection was 
lower compared to the control. As a control, polyA, a polynucleotide consisting of 
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only ATPs, was transfected. polyA is supposed to be non-immunogenic (Tobias 
Schmidt, personal communications). Therefore, transfection of neither modified nor 
unmodified mRNA seems to have an impact on IFN! expression in I3 hESCs. 
However, hiPSCs of the iLB-30-r21 line showed a 500fold increased IFN! expression 
upon transfection with unmodified mRNA. This indicates an immune response that 
only takes place upon transfection with unmodified mRNAs, even though the intensity 
of this response is low compared to the immune responses of fibroblasts. The fact 
that this immune response could only be detected in hiPSCs and not in hESCs could 
suggest that induced PSCs remain an immune status of the cells they were 
originated from. iLB-30-r12 iPSCs were reprogrammed from human fibroblasts. The 
weak immune response of the cells upon transfection with unmodified mRNA could 
be a relic of the fibroblast innate immune system. lt-NES cells, that were 
differentiated from the iLB-30-r12 iPSC line, did only show a 1.6 fold upregulation of 
IFN! expression, though. This contradicts the hypothesis that iLB-30-r12 cells remain 
the immune response of its origin fibroblasts at least partially; if this was the case, lt-
NES cells should react upon transfection with unmodified mRNA more strongly. To 
further enlighten the immunogenic properties of hPSCs and lt-NES cells, further cell 
lines should be investigated. 
If the observed effect of immune response of iLB-30-r12 hiPSCs is a real biological 
effect, it has to be noted that the upregulation of IFN! already occurs six hours after 
transfection and is decreased strongly 24 hours after transfection. This could suggest 
that the immune response not only is attenuated in hPSCs, but also accelerated. It 
may be that the immune response in the I3 hESCs already was finished six hours 
after mRNA transfection. Therefore, also for hPSCs the time course of innate 
immune system response needs further examination. In the literature, no studies 
report an accelerated response of the innate immune system. In the literature it is 
reported that the innate immune responses in stem cells are attenuated, whereas 
these studies do not speculate about an acceleration in these processes (Chen et al., 
2010; Földes et al., 2010; Hong & Carmichael, 2013). Földes et al. furthermore 
reported that cells differentiated from hPSCs, in that case endothelial cells, preserve 
the immune response of the origin cells (Földes et al., 2010). This is contradictory to 
the findings in this thesis, as lt-NES cells differentiated from hiPSCs, showed not the 
same immune response as the origin cells. This is also contradictory to the findings 
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of Chen et al. who showed that BMP4 induced differentiation of hPSCs led to a gain 
of IFN! responses (Chen et al., 2010).  
Another study from 2013 reported that innate immune responses are enhanced upon 
neural differentiation of hESCs (Farmer et al., 2013). However, neural precursor cells 
showed an attenuated immune response, which is consistent with the findings 
presented in this thesis. Further analysis of differentiated cells could enlighten the 
innate immunity upon differentiation.  
 
All in all, the knowledge of the innate immunity of human pluripotent stem cells still is 
poor. But the published data together with this thesis show the same trend. Innate 
immunity in hPSCs is attenuated; transfection either with PAMPs or with mRNA does 
not lead to induction of Interferon mediated effects. The reasons for this remain 
unclear. It is known that during pregnancy, the maternal immune system also 
protects the embryo; it does not posses either an own innate or adapted immune 
system. In case of an infection, the placental barrier usually prevents an infection of 
the embryo. Furthermore, different tissues of the placenta express TLRs, suggesting 
that the placenta is also responsible for the protection of the embryo against 
pathogens (Holmlund et al., 2002). Therefore, the innate immunity of trophoblasts 
would also be an interesting subject of research.  
The evolutionary advantage of a lacking innate immune system remains unclear, as 
a good defense against pathogens should be a benefit for an organism. It can be 
speculated that the harm of a pathogenic infection would be too high in an early 
phase of development to put effort in the defense against it. The fact that activation of 
innate immune response in trophoblast cells lead to apoptosis and therefore to 
abnormal pregnancy outcomes indicate also a strategy that prevents fight against 
pathogens (Abrahams & Mor, 2004; Jerzak & Bischof, 2002).  
Interestingly, the results reported in this thesis show that human and murine PSCs 
resemble in their immunogenic potential. As reported several times by a group 
around Wang, murine PSCs show attenuated innate immunity activation upon viral 
infection (Wang et al., 2013, 2014). Wang et al. also claim that these unique 
properties can be exploited for mRNA mediated gene expression strategies (Wang et 
al., 2014). 
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Taken together, hPSCs can be transfected efficiently with unmodified mRNA, as the 
innate immunity is not activated. The reasons for the stronger efficiency and intensity 
upon transfection with unmodified mRNA still remain unclear. However, in case of 
manipulation of hPSCs, advantage of the attenuated innate immunity can be taken. 
But in other fields of research, the missing innate immune system can be a 
disadvantage. If cells differentiated from hPSCs keeps some of the characteristics of 
the immune system of the pluripotent cells, transplantation of these cells could hold 
the risk that these cells can be infected with pathogens. These pathogens could 
replicate in these cells and then exist in a number high enough to overcome the 
innate immune system of the other somatic cells.  
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4.6 Outlook 
In this thesis it has been shown that Stat3 signaling seems not to play a role in 
adherent hPSC culture. Nonetheless, it would be interesting to check whether the 
signal-transducing transmembrane protein gp130 is expressed on the surface of 
hPSCs. With that, it could be excluded whether the deficiency of the IL-6/sIL-6R 
chimeric fusion protein to phosphorylate Stat3 is due to the lack of gp130. 
The described data functions as a proof-of-principle. In order to confirm that Stat3 
signaling plays no role in hPSCs, several other hiPSC and hESC lines should be 
included. Moreover, the expression of other Stat3 downstream target genes should 
be examined via qRT-PCR.  
Furthermore, it could be a feature of the chimeric fusion protein to induce Stat3 
signaling only in human pluripotent stem cells. To exclude this, naïve human PSCs 
would be the perfect model. The recently published protocol to gain naïve hPSCs 
from Gafni et al. could be used to obtain bona fide naïve hPSCs (Gafni et al., 2013). 
Furthermore, the adaption of this protocol to cells in which Stat3 is inactivated by 
TALEN technology would be interesting. 
For that, the TALEN mediated Stat3 editing has to be improved. First of all, clones 
should be derived, as in the polyclonal cell populations only 5% of the cells show a 
Stat3 editing. In polyclonal cultures, the not targeted cells could have a growth 
advantage and therefore overgrow the cultures. In order to facilitate the obtainment 
of clonal Stat3 edited hPSC lines, the efficiency of the TALEN mRNA transfection 
should be improved. To reach this, unmodified TALEN mRNAs should be generated, 
since it was shown that hPSCs can be transfected more efficiently with unmodified 
synthetic mRNAs. Furthermore, additional transfection rounds could improve the 
outcome, as the mRNA transfections do not seem to effect cell survival.  
 
It has been shown in this thesis that the replacement of the modified ribonucleotides 
with their unmodified counterparts leads to an improved transfection of synthetic 
mRNA into hPSCs. The modifications of ribonucleotides are not the only 
posttranscriptional modifications of mRNA that occur in vivo to prevent the activation 
of the innate immune system. Furthermore, mRNA gets “capped”, meaning that at 
the 5´-end of the RNA, a methylated guanine nucleotide is added (Alberts et al., 
2002). As the removal of the nucleoside modifications led to increased transfection 
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efficiency, the effect of further reduction of modifications would be interesting. It could 
be investigated whether hPSCs can be transfected with completely unmodified 
mRNA. Additionally, cells could be transfected with mRNAs synthesized with 
modified ribonucleotides but without the 5´-Cap and thus enlighten the impact of the 
different modifications to the innate immune activation and to the half-life of the 
mRNAs. Skipping the capping in the mRNA synthesis would greatly reduce costs of 
in vitro mRNA synthesis, but probably lead to problems in translation.  
 
The innate immune system of hPSCs still is poorly understood; a lot of experiments 
still can be performed to further elucidate its role in pluripotent cells as well as in 
multipotent precursors and derivatives of both. First of all, the expression of different 
receptors of the TLR family could be investigated; of special interest in case of RNA 
transfection would be the TLR3 receptor. Also the expression of TLR7 should be 
investigated, as this receptor also recognizes pathogenic RNA. Further, other 
mediators of RNA-induced immune response, such as RIG-I or the PKR, should be 
tested for its expression in hPSCs. Additionally it would be interesting to check the 
expression of the key modulators in trophoblast cells, as it was reported that this 
extraembryonal tissue seems to be responsible for the protection of the embryo 
proper.  
As the response upon mRNA transfection is mediated by Interferon !, its expression 
should be investigated more in detail. In this thesis, expression levels were checked 
only at two time points after transfection. As the IFN! expression in fibroblasts could 
be detected only relatively late, further time points between the analyzed 6 and 24 
hours would be interesting. The presented data in this thesis gave the hint that 
immune response in hPSCs could be not only attenuated, but also accelerated; 
therefore, it would be interesting also to look for IFN! expression at earlier time 
points, for example 1,2 and 4 hours after mRNA transfection.  
The IFN! expression of the two analyzed hPSC lines differed; therefore, additional 
cell lines should be investigated. Of special interest would be the examination of 
IFN! expression upon reprogramming and differentiation. To accomplish that, the 
iLB-30-r12 cells could be used, as from this line fibroblasts, iPSCs and neural 
precursors already are established. Further differentiation of the iLB-30-r12 lt-NES 
cells into mature neurons would create fully differentiated somatic cells. 
Differentiation into different cell types, also from different lineages, could be achieved 
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without big effort. With that, effects depending on the biological variety can be 
excluded, as all cells originate from the same background. Not only IFN! expression, 
but also TLR3 expression, would be of interest. To confirm that TLR3 is the mediator 
of the innate immune response upon mRNA transfection, also the expression and 
activation of TLR7 should be investigated. 
Finally, also the activation of the innate immune system upon contact with other 
PAMPs should be investigated to find out whether also other PRR-mediated immune 
reactions are attenuated in hPSCs.  
4.7 Conclusion 
In this thesis it has been shown that the chimeric IL-6/sIL-6R fusion protein cannot 
maintain pluripotency in hPSCs. It failed to activate Stat3 signaling in hPSCs, and 
application to mPSCs and HepG2 revealed that this LIF agonist is not as potent as 
LIF itself. The results still need to be confirmed in different cell lines. 
It was shown that functional synthetic TALEN mRNAs against Stat3 can be 
generated. Transfection into hPSCs resulted in an editing efficiency of the Stat3 gene 
of 5%.  
Synthetic mRNAs represent a robust tool to manipulate hPSCs as they could be 
transfected efficiently. Furthermore, hPSCs as well as their derivatives lt-NES cells 
could be transfected more efficiently with unmodified than with modified synthetic 
mRNA, whereas human fibroblasts showed opposite results. Fibroblasts could be 
transfected with unmodified synthetic mRNA when IFN signaling was inhibited. This 
led to the suggestion that the immune response in hPSCs upon synthetic mRNA 
transfection is attenuated. This assumption was supported by the fact that hPSCs 
and lt-NES cells show low IFN! expression upon synthetic mRNA transfection.  
This knowledge may be useful to further improve mRNA mediated hPSC 
manipulation such as genomic engineering with synthetic TALEN mRNAs.  
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5 Summary 
Human pluripotent stem cells (hPSCs) hold great promises as a model for 
development as well as a source for cells in regenerative medicine. Although hPSC 
research came into focus in the last decade, many aspects of the biology of hPSCs 
still remain unclear. Maintenance of pluripotency in murine pluripotent stem cells 
(mPSCs) depend on LIF-activated Stat3 signaling, whereas human PSCs appear not 
to require activation of this signaling pathway. In order to investigate the potential role 
of Stat3 signaling in hPSCs, cells were treated with a chimeric fusion protein (“IL-
6/sIL-6R”). The chimeric fusion protein is supposed to be a potent LIF agonist and 
thus Stat3 signaling activator. While it was reported before that hPSCs can be 
maintained pluripotent in suspension cultures in the presence of the chimeric protein, 
here IL-6/sIL-6R failed to maintain pluripotency in adherent cultures. Activation of 
Stat3 signaling could be observed neither at protein nor at mRNA level. To further 
analyze the role of Stat3 in hPSCs, a targeted gene inactivation should be 
established. Classical DNA transfection methods did not lead to an efficient editing. 
Previously, synthetic mRNA could be transfected into hPSCs with an efficiency up to 
78%. Therefore, synthetic Transcription Activator-like Effector Nuclease (TALEN) 
mRNAs targeting the Stat3 locus were generated. Synthetic TALEN mRNAs edited 
the hPSC genome with an efficiency of 5%.  
In order to improve efficiencies, transfection with several types of synthetic mRNAs 
should be investigated. Synthetic mRNAs usually contain modified nucleotides in 
order to prevent innate immunity activation. In order to investigate if innate immunity 
plays a role in hPSCs, it was tested whether synthetic mRNAs without modified 
nucleotides (“unmodified mRNA”) can be used. As a proof of principle, hPSCs and 
their derivatives lt-NES cells (multipotent neural precursors) were transfected with 
unmodified GFP mRNA. Surprisingly, the average efficiency (51.57% for hPSCs; 
43.63% for lt-NESCs) was even higher than for transfection with modified GFP 
mRNA (41.83% for hPSCs; 28.87% for lt-NESCs). Furthermore, the fluorescence of 
the translated protein appeared to be stronger. Human fibroblasts, representing 
somatic cells, could be transfected more efficiently (59.57%) with GFP mRNA 
synthesized with modified nucleotides. Unmodified GFP mRNA transfection resulted 
in low efficiency (42.08%) and weak fluorescence intensity, most likely due to innate 
immunity responses.  
Summary 
 
! 110 
In order to test whether attenuated immune response is the reason for accessibility 
for unmodified mRNAs, the innate immunity associated Interferon signaling was 
blocked using the inhibitor B18R. Inhibition of Interferon signaling in human 
fibroblasts resulted in an increase of efficiency from 32.5% up to 59.35% when 
unmodified mRNA was transfected.  
Moreover, fibroblasts expressed higher levels of IFN! upon transfection with 
unmodified mRNA compared to hPSCs and lt-NES cells. Together, this let suggest 
that the IFN! mediated immune response is attenuated in multi- and pluripotent cells. 
These findings may be of interest for further applications of synthetic mRNAs in 
hPSCs. For example, generation of unmodified synthetic TALEN mRNAs should lead 
to improved genetic engineering. 
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